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ABSTRACT
ANALYSIS OF BRCÁ1 AND BRCA2 GENES IN TURKISH BREAST CANCER
PATIENTS
Hilâl Ö zdağ
Ph.D. in Molecular Biology and Genetics 
Supervisor: Assoc.Prof. Tayfiin özçelUc 
June 2000,165 Pages
Breast cancer is the most frequent cancer type and the second cause of death among 
women. It is estimated that 10 to 15% of breast cancer cases are hereditary. The majority 
of hereditary breast cancers can be attributed to germ-line mutations in ^Jgeast CAncer 
susceptibility genes BRCAl and BRCA2.
In this study, germ-line BRCAl and/or BRCA2 gene mutations were screened in 50 
Turkish breast and/or ovarian cancer patients divided into four groups of hereditary, 
familial, early onset, and male cancer by heteroduplex analysis and DNA sequencing. 
Two BRCA2 mutations, one novel (6880insG) and one previously reported 
(3034delAAAC), were found in the hereditary group. A novel BRCAl (1200insA) 
mutation was formd in the early onset group. All three mutations cause premature- 
termination codons. In addition, five BRCAl sequence variants have been identified in 
23 patients. K654E (2080 A—>G), D693N (2196 G ->A ), P871L (2731 C—>T), and 
K1183R (3667 A—>G) result in a change of amino acids. 1013 T— >^C and 2201 C—>T 
are silent mutations. One patient in the early onset group was compound heterozygote 
for K654E and D693N. These results indicate that BRCAl and BRCA2 genes are 
involved in some but not all hereditary breast cancers in the Turkish population.
Ill
ÖZET
TÜRK MEME KANSERİ HASTALARINDA RRC4İ VE BRCA2 GENLERİNİN
İNCELENMESİ
Hilâl özdağ
Moleküler Biyoloji ve Genetik Doktorası 
Tez Yöneticisi: Doç. Dr. Tayfun özçelik 
Haziran 2000,165 Sayfe
Meme kanseri kadmlar arasmda en sık görülen kanser tipidir ve ölüm nedenleri arasmda 
ikinci sırada yer alır. Meme kanseri olgularmın %10 ile 15’inin kalıtımsal olduğu tahmin 
edilmektedir. Kalıtımsal meme kanserlerinin büyük bir kısmı BRCAl ve BRCA2 Meme 
Kanseri yatkınlık genlerindeki eşey hücre mutasyonlanna atfedilebilir.
Bu çalışmada kalıtımsal, ailesel, erken yaş ve erkek meme kanseri gruplanna aynimış 50 
Türk meme ve/veya över kanser olgusunda BRCAl ve /veya BRCA2 eşey hücre 
mutasyonlan heterodupleks analizi ve DNA dizilemesi ile taranmıştır. Kalıtımsal meme 
kanseri grubunda biri yeni (6880insG) biri önceden bildirilmiş (3034delAAAC) iki 
BRCA2 mutasyonu saptanmıştır. Erken yaş grubunda yeni bir BRCAl mutasyonu (1200 
insA bulunmuştur. Her üç mutasyonun da proteinde erken sonlanma kodonu oluşumuna 
neden olduğu tespit edilmiştir. Ayrıca 23 hastada beş adet BRCAl dizi varyantı 
tanımlanmıştır. Bunlardan K654E (2080 A ^G ), D693N (2196 G->A), P871L (2731 
C->T) ve K1183R (3667 A->G) tranzisyonlan aminoasit değişimine yol açmaktadır. 
1013 T ^ C  ve 2201 C-^'T ise sessiz mutasyonlardır. Erken yaş grubundaki bir hastanın 
K654E ve D693N için “compomıd”heterozigot olduğu tespit edilmiştir. Bütün bu 
sonuçlar BRCAl ve BRCA2 genlerinin Türk popülasyonundaki kalıtımsal meme 
kanserlerinin bir kısmmda rol aldığım ortaya koymaktadır.
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1. INTRODUCTION
Cancer is one of the leading causes of death in human populations'. There have been 
many studies that aim to elucidate the mechanism of turnorigenesis, and many attempts 
to cure cancer in the 20 century. These efforts accumulate a huge amount of data about 
the nature and mechanism of tumorigenesis. Although the accumulated data is just the 
tip of the iceberg, it is now known that cancer appears as a result of the disruption of the 
genomic integrity. This disruption may arise in chromosomal or gene levels. In both 
ways there is either a gain (oncogene) or a loss (tumor supressor) of function of a 
particular set of genes that control the growth and the life time of a cell (Haber and 
Harlow, 1997). Thus the researches dealing with tumorigenesis are focused on either 
oncogenes or tumor supressor genes at several different scopes, all aiming to find out the 
underlying mechanisms of a cell’s life cycle.
Disruption of genomic integrity may occur in several different ways. It may develop 
sporadically, because of epidemiologic factors, lifestyle, or it may be hereditary. In 
either case, genomic integrity is disrupted. Recent experimental data has shown that 
some individuals are more susceptible to cancer because of their genomic heritage. 
Actually, more than a century ago, Paul Broca described four generations of breast
(WHO Report 1998)
cancer in his wife’s family which underlined, probably for the first time, contribution of 
the heredity factor in tumorigenesis (Lynch etal. 1994).
Breast cancer is the most frequent cancer type and the second cause of death among 
women. Like many other cancer types, breast cancer may arise sporadically or 
hereditary factors may contribute to its development. It is estimated that 10 to 15% of 
breast cancer cases are hereditary (Feunteun 1999). In 1994 and 1995, as a result of an 
international collaboration of many research groups, two loci have been found to be 
linked to hereditary breast cancer (Miki et a/. 1994, Wooster et al. 1995). The 
subsequently identified genes were named as ^ e a s t  Cancer susceptibility genes 
BRCAl and BRCA2 are now considered to be responsible for approximately 60% of 
hereditary breast cancer cases based on mutation analysis studies in many different 
populations (Szabo and King 1997). Functional studies, although not complete, show 
that these two genes are tumor suppressors that have roles in the maintenance of 
genomic integrity as caretakers (Vogelstein and Kinzler 1998).
Characterization of the mutations of a particular gene renders important information 
regarding the function of that gene. Besides, documentation of the mutation spectrum of 
a gene is one of the most reliable reflection of a population’s dynamics. The BRCAl and 
BRCA2 mutation status of most Western populations has been studied during the last 
five years. However, there is not enough data on these two structurally gigantic genes’ 
status in Eastern populations. Breast cancer is among the most common malignancies in 
Turkish women (Karaoguz and içli, 1993). The frequency and the types of germ-line 
mutations involved in Turkish breast/ovarian cancers are not well known. In order to
determine the contributions of BRCAl and BRCA2 mutations to the development of 
breast/ovarian cancer in the Turkish population, we screened pre-selected regions of 
these genes in four groups of patients composed of hereditary and familial cancer. As 
well as early onset and male breast cancer.
1.1. Cancer
Cancer is a common term used for all malignant tumors, and 2.3 million individuals die 
(Table 1) from cancer each year according to the 1998 estimates of WHO (The World 
Health Report, 1999). Although the ancient origins of this term is somewhat uncertain, it 
probably derives from the Latin for crab, “cancer”, presumably because a cancer 
“adheres to any part that it seizes upon in an obstinate manner like the crab”. Neoplasia 
means “new growth”. The term tumor was originally applied to the swelling caused by 
inflammation. Neoplasms also may induce swellings, and by long precedent the non- 
neoplastic usage of tumor has passed into limbo; thus, the term is now equated with 
neoplasm. Oncology (greek “oncos”= tumor) is the study of tumors or neoplasms 
(Robbins S. et al, 1984). Since the beginning of the century, researchers have studied 
cancer to understand the mechanisms of tumorigenesis. The original concept of negative 
regulators of tumor development can be traced to the earliest deseriptions of cancer as a 
genetic disease. The earliest known reference is to the German cell biologist Theodor 
Boveri, who proposed in 1902 that cancer might arise from the effects of both positive 
and negative regulators (Haber D. and Harlow E., 1997). It is known for many years that 
cancer arise as the result of genetic disruption which leads the cell to be immortalized 
and to proliferate in an uncontrolled fashion.
Table 1. Leading cause of death and their mortality rates in WHO member states
Mortality in WHO Member States
rank % o f  total (000)
Botth s«*es ..;, ..'kjAk;.. .............^
Ischaemic heart disease 1 13.7 7 375
Cerebrovascular disease 2 9.5 5 106
Acute lower respiratory infections 3 6.4 3 452
HIV/AIDS 4 4.2 2 285
Chronic obstructive pulmonary disease 5 4.2 2 249
Diarrhoeal diseases 6 4.1 2219
Perinatal conditions 7 4.0 2 155
Tuberculosis 8 2.8 1 498
Cancer of trachea/bronchus/lung 9 2.3 1 244
Road traffic accidents 10 2.2 1 171
.'.¡'v J..
Ischaemic heart disease 1 12.8 3 659
Cerebrovascular disease 2 8.2 2 340
Acutelowerrespiratory infections 3 6.1 1 753
Chronic obstructive pulmonary disease 4 4.3 1 240
fflV/AIDS 5 4.1 1 164
Diarrhoeal diseases 6 4.0 1 149
Perinatal conditions 7 3.9 1 121
Cancer of trachea/bronchus/lung 8 3.2 911
Tuberculosis 9 3.1 893
Road traffic accidents 10 3.0 855
S k /k k A 'i .
Ischaemic heart disease 1 14.6 3 717
Cerebrovascular disease 2 10.9 2 766
Acutelowerrespiratory infections 3 6.7 1 699
HIV/AIDS 4 4.4 1 121
Diarrhoeal diseases 5 4.2 1 070
Perinatal conditions 6 4.1 1 034
Chronic obstructive pulmonary disease 7 4.0 1 010
Tuberculosis 8 2.4 605
Malaria 9 2.1 538
Measles 10 1.7 432
Genetic disruption leading to tumorigenesis cause either a negative regulation -  loss of 
function of tumor supressor genes, or a positive regulation -  gain of function of 
oncogenes, in a cell’s life cycle. Tumorigenesis is a multistep process. Thus the genetic 
disruption is an accumulation of many genetic alterations. Some individuals are 
genetically susceptible to cancer, although most of the cases arise sporadically. This 
susceptibility comes from what is termed as “the first hit” . Knudson postulated that 
individuals with an autosomal dominant cancer susceptibility inherited a germ-line 
mutation in one of the alleles of a particular gene and that subsequent genetic alterations 
were required for tumor formation. Over the years Knudson’s hypothesis was refined to 
include a second hit at the same locus to inactivate the remaining normal allele. The past 
decade has seen numerous molecular confirmations of Knudson’s hypothesis (ex. APC, 
R B) and concrete demonstration of the multiple genetic events required for 
tumorigenesis (ex. colon cancer) (Vogelstein and Kinzler, 1997).
1.2. Oncogenes
For many years it has been realised that damage to the DNA of a cell (mutation) is 
associated with changes that lead to cancer. It was initially believed that the genetic 
mutations responsible for cancer caused a deletion of essential regulatory genes 
restraining cell growth. Evidence for this has also come from cell fusion studies, which 
implied that malignant cells have lost functions that are dominantly expressed in normal 
cells, and are capable of suppressing malignancy. However, the discovery of retroviruses 
radically changed these ideas concerning the alterations that occur to genes in cancer; it 
led to the discovery of oncogenes and gave a new perspective of cancer as being caused
by genes that actively promote uncontrolled growth. The vast majority of non-viral 
oncogenes appear to be altered forms of cellular genes that encode proteins that 
participate in the pathway of cellular proliferation. The normal, intact cellular genes are 
known as proto-oncogenes. Cells receive signals to proliferate via growth factors that 
bind to receptors located on the outside surface of the cell. The signal is then transmitted 
into the cell, across the cytoplasm to the nucleus. There, the signal is converted into a 
growth response by means of transcriptional activation of the genes for proliferation. As 
a general rule, oncogenes are mutated forms of the cellular proto-oncogenes which 
encode the components of this signalling pathway. Direct comparisons of the DNA 
sequences of normal proto-oncogenes with their mutated oncogene derivatives have 
revealed the mechanisms by which proto-oncogenes become activated. Activation can 
occur either by changes to the coding sequence of the proto-oncogene so that a mutated 
protein -an oncoprotein- is produced with aberrant biochemical properties; or it can 
occur by mutations that deregulate the levels, and/or timing, of expression of the 
structurally unaltered proto-oncogene (Cooper GM, 1995).
The result of proto-oncogene activation is the gain of function in genes signalling 
proliferation to occur in cells which should not normally be proliferating. This 
inappropriate cell division will disrupt the normally ordered differentiation program of 
the cell. These activation processes can occur in a number of ways, which do not 
necessarily involve alteration of the structure of the proto-oncogene, but rather its forced 
expression at times in the development of the cell when proliferative genes should be 
silent and differentiative genes should be expressed (Burck KB et al, 1988).
Similarly, just as the overexpression of a normal gene product at the inappropriate time 
can lead to partial cell transformation, so the alteration of the coding sequence of a 
proto-oncogene can change the function of the protein product so that it relays its 
proliferative signals inappropriately. Such activation events can occur by deletions of 
portions of the coding sequence, by fusion of the sequence to other protein domains that 
alter the activity of the signalling domain, or by point mutations to the sequence at 
critical bases such that the amino acid sequence of the protein product is critically 
altered. The ras class of proto-oncogenes can become oncogenic by a change as small as 
a single base being changed in the sequence of the gene (Vile R., 1992)
1 .3 . Tumor suppressors “Gatekeepers and Caretakers”
The molecular concepts of tumor suppressor genes stem from three lines of experimental 
evidence. The first is explained by Knudson’s model predicting the development of the 
childhood tumor retinoblastoma requires two rate-limiting genetic hits, subsequently 
shown to represent mutations of both alleles of a tumor suppressor gene. The hypothesis 
that children with inherited susceptibility to retinoblastoma harbour a germline hit, while 
sporadic cases have two somatic mutations, was confirmed with the cloning of the RB 
gene. A second essential observation was the fact that these genetic hits consisted of 
loss-of -function mutations. Loss of heterozygosity showed how loss of genetic material 
was the mechanism by which recessive mutations became manifest. A third 
experimental avenue was explored by Harris and co-workers in 1969, who found they 
could suppress the malignant phenotype by fusion of cancer cells with non-transformed 
cells.
Many of the known tumor suppressor genes, including RB,p53, WTl, APC andp l6 , 
fulfill these basic early predictions-loss-of-function mutations, inactivation in both 
familial and sporadic tumors, and rescue of the tumor phenotype by the wild-type allele. 
For example, the classical concept that re-introduction of tumor suppressors into 
malignant cells inhibits their proliferation, is challenged by the new class of genes 
implicated in genomic integrity and DNA repair, whose loss leads to genetic damage 
that cannot be remedied simply by restoration of a wild-type allele.
The functions of known tumor suppressor genes are in a wide range of different cellular 
pathways. The current family of tumor suppressors includes DNA-binding transcription 
factors (p53 and WTl), genes that may indirectly modulate transcriptional regulation 
{RB, APC, possibly BRCAl), an inhibitor of kinases required for cell-cycle progression 
(pl6), a cell stmctural component (NF2), a novel phosphatase (PTENM M ACl), a 
potential mediator of mRNA processing (VHL), and genes implicated in signaling 
pathways including those of ras (NFl, TGF) Tumor suppressor genes involved in DNA 
repair and genomic stability (MSH2, MLHl, BRCAl and BRCA2) have also been 
described as caretakers.
Actually, recently Vogelstein and Kinzler divided most tumor suppressors broadly into 
two groups, named as “gatekeepers” and “caretakers” (Figure 1). Gatekeepers are genes 
that directly regulate tumor development by inhibiting its growth or by promoting its 
death. The functions of these genes are rate limiting for tumor growth, and as a result 
both the maternal and paternal copies of these genes must be inactivated for a tumor to
8
develop. The identity of gatekeepers varies with each tissue, such that inactivation of a 
given gene leads to specific forms of cancer predisposition. Because gatekeeping genes 
are rate limiting for tumor initiation, they tend to be frequently mutated in sporadic 
cancers through somatic mutation as well as in the germline of predisposed individuals.
In contrast, inactivation of caretakers does not directly promote growth of tumors. 
Rather, inactivation of caretakers leads to a genetic instability that only indirectly 
promotes growth by causing an increased mutation rate. Because numerous mutations 
are required for the full development of a cancer, inactivation of caretakers, with the 
consequent increase in genetic instability, can greatly accelerate the development of 
cancer (Vogelstein B. 1998).
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Figure 1. Caretaker-Gatekeeper Model (from Kinzler and Vogelstein, 1997).
Neoplasms constitute the most important lesions of the female breast. A great variety of 
tumors may occur in the female breast, made up as it is of a covering integument, adult 
fat, mesenchymal connective tissue, and epithelial structures (Robbins ei al, 1984). 
Breast cancer is the second leading cause of death among women of all ages according 
to the National Cancer Institute statistics. It becomes the first leading cause of death 
among women with age between 15-54.
1. 4. Breast cancer
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Figure 2. Main anatomic structures of breast, (from NCI database)
Each breast has 15 to 20 overlapping sections called lobes. Within each lobe are many 
smaller lobules, which end in dozens of tiny bulbs that can produce milk. The lobes.
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lobules, and bulbs are all linked by thin tubes called ducts. These ducts lead to the nipple 
in the center of a dark area of skin called the areola. Fat fills the spaces around the 
lobules and ducts. There are no muscles in the breast, but muscles lie under each breast 
and cover the ribs. Each breast also contains blood vessels and vessels that carry 
colorless fluid called lymph. The lymph vessels lead to small bean-shaped organs called 
lymph nodes. Clusters of lymph nodes are found near the breast in the axilla (under the 
arm), above the collarbone, and in the chest. Lymph nodes are also found in many other 
parts of the body.
Breast carcinoma arises from the epithelium of the mammary gland, which includes the 
milk-producing lobules and the ducts that carry milk to the nipple. Malignant 
transformation of the stromal, vascular, or fatty components of the breast is not included 
in this definition and is extremely rare. The transition from normal to malignant breast 
epithelium has not been as well studied as the parallel changes in colonic epithelium; 
however, there is increasing evidence that the breast epithelium undergoes a 
transformation from normal to hyperplastic, followed by the appearance of atypia in 
association with the hyperplasia, ultimately becoming malignant. Malignant cells 
continue to evolve from noninvasive carcinoma, typified by in situ to invasive 
carcinoma, and ultimately to cells with metastatic potential (Kinzler and Vogelstein,
1997). Breast cancer is generally classified as invasive or non-invasive. Invasive cancer 
originates in the lobules and/or milk ducts, while while non-invasive or in situ cancers 
are confined to the lining of the lobules or ducts. The most important criteria for 
assessing future risk of invasive disease is to determine whether cancer cells have 
invaded the lymph nodes. Breast cancer is commonly categorized into three grades
11
according to growth rate. Well-differentiated tumors are termed as grade I; moderately 
differentiated tumors as grade II; and poorly differentiated tumors are termed as grade 
III. The most common type of breast cancer begins in the lining of the ducts and is 
called ductal carcinoma. Another type, called lobular carcinoma, arises in the lobules. 
When breast cancer spreads outside the breast, cancer cells are often found in the lymph 
nodes under the arm (axillary lymph nodes). If the cancer has reached these nodes, it 
may mean that cancer cells have spread to other parts of the body—other lymph nodes 
and other organs, such as the bones, liver, or lungs via the lymphatic system or the 
bloodstream.
The treatment and prognosis of a women with breast cancer are strongly influenced by 
the stage at the time of diagnosis. Multiple staging systems have been proposed, but the 
most commonly used system is the one adopted by both the American Joint Committee 
(AJC) and the International Union against Cancer (UICC). This staging system is a 
detailed TNM (tumor, nodes, metastasis) but can be summarized as in Table 2.
Table 2. TNM Staging
Stage 0 Carcinoma in situ
Stage I Tumor 2 cm, axillary nodes not involved
Stage II Tumor between 2 and 5 cm and/or involved but mobile axillary lymph nodes 
Stage III Tumor larger than 5 cm and/or fixed axillary lymph nodes; includes 
inflammatory breast cancer
Stage IV Distant métastasés beyond ipsilateral axillary lymph nodes
12
There are several determinants of breast cancer occurrence such as reproductive history, 
diet and alcohol consumption, endogenous hormones and estrogen receptor expression, 
and exogenous hormones. There are many case-control studies analyzing the effect of 
reproductive factors on breast cancer. The possibility of a protective effect for mothers 
of twins versus mothers of single births (odds ratio 0.7) received support from a large 
nested case-control study conducted in Sweden (Murphy et al, 1997). This association 
may be correlated with either to the influence of hormonal characteristics of pregnancy 
or to genetic differences between women who give birth to twins and those who do not. 
Women appear to be at higher risk of developing breast cancer during or shortly after 
pregnancy, and the prognosis for such pregnancy associated breast cancers was observed 
to be poorer than for tumors unrelated to pregnancy (Bonnier,, et al, 1997). The possible 
influence of lactation on the risk of breast cancer is also under investigation. Some 
recent studies suggest that there is a protective association between breast feeding and 
breast cancer among both premenopausal and postmenopausal women (Enger et al,
1997).
Numerous studies have reported on the relationship between drinking alcohol and breast 
cancer, and the results have tended to indicate that alcohol consumption is associated 
with a slightly increased risk of breast cancer (Schatzkin, et al 1994)
1. 4.1. Etiology of breast cancer
13
Hormone replacement therapy is used in cardiovascular disease, in osteoporosis, and in 
the relief of menopausal symptoms. An analysis of studies on this topic showed that 
current hormone replacement therapy users were approximately 20% more likely to 
develop breast cancer than those who never used this therapy. The risk decreases in a 
nonuser 5 year after cessation of use (Coll. Group on Horm. Fact. In Breast Ca, 1997). 
These results suggest that estrogen acts late in the sequence of breast carcinogenesis and 
its tumor-promoting effects may be reversible (Alberg et al, 1998).
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Evidence concerning reproductive history and exogenous estrogen use suggest that 
estrogen is involved in the etiology of breast cancer (Alberg et al 1998). Several studies, 
including a multi country study for the World Health Organization, suggest that oral 
contraceptives (used by 61 million women worldwide) are associated with a relative risk 
of 1/3 to 1/5 for breast cancer that will be diagnosed before the age of 40-45 (Hulka and 
Stark, 1995).
That hormones influence risk and prognosis of breast cancer has been known for 
decades. Breast cancer is rare in men, suggesting an influence of sex-steroid hormones. 
Women who have had bilateral oophorectomy early in life are at markedly reduced risk 
of subsequently developing breast cancer; the earlier oophorectomy is done, the greater 
the reduction. Early age at menarche (11 years or less) and late age at natural menopause 
(55 or older) are associated with increased risk (Hulka and Stark, 1995). Antiestrogens 
are employed clinically because of their ability to inhibit the growth of breast cancer 
cells. In addition, disease progression inevitably occurs, indicating a transition to 
hormone resistance even in the presence of the estrogen receptor (Eisen and Weber,
1998). The responsiveness of breast tissue to estrogen exposure would be expected to 
lead to differences in susceptibility to breast cancer. This is supported by the results of a 
case-control study which showed that the normal breast tissue of women with breast 
cancer was three times more likely than the breast tissue of the control patients to have 
estrogen receptor overexpression (Khan, et al, 1997).
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1.4.2 Genetic factors in Breast Cancer
I.4.2.I. Somatic Mutations in Breast Cancer
The study of sporadic breast cancers is important in order to understand the pathogenesis 
of breast cancer. Sporadic breast cancer which constitutes approximately 90% of all 
breast cancer cases, have fundamental molecular genetic differences. These somatic 
alterations are in growth factors and receptors, intracellular signalling molecules, 
regulators of cell cycle, adhesion molecules and proteases. In addition, LOH of many 
loci, such as chromosomes 17p, 17q, 16q, 13q, lip . Ip, 3p and 18q (Cleton-Jansen, 
1994; Gudmundsson, 1993; Cropp,1993; Mathew, 1994; Dorion-Bonnet, 1995).
Members of the epidermal growth factor receptor (EGFR) family are frequently altered 
in sporadic breast cancer. These proto-oncogenes, EGFR, erbB-2 or HER-2, and erbB4, 
become oncogenic through gene amplification or overexpression resulting in the 
aberrations in signal transduction pathways and thus deregulation of cellular 
proliferation (Bacus, 1994).
Disruption of the cell cycle checkpoints leads to uncontrolled growth and cancer. The 
tumor suppressor protein p53 which is known also as genome guardian, plays a central 
role in regulating progression through cell cycle. p53 Alterations in breast cancer are 
shown by analyzing the coding region for mutations or using antibody demonstrating 
aberrant localization or altered levels of the protein. p53 mutations have been detected in
17
15 to 45% of human breast cancer specimens in several studies (Deng ei al, 1994; 
Andersen et al, 1993; Saitoh et al, 1994)
Like p53, RB regulates cell cycle progression. Dephosphorylated RB inhibits cellular 
proliferation by halting cell cycle progression in Gl. Structural rearrangements and 
inactivation of RB is detected in breast cancer (T’ang et al, 1988; Lee et al, 1988). In 
addition it is shown that estradiol decreases expression of RB (Gottardis et al, 1995). 
Another growth inhibitory protein TGF-(3 which is shown to be hormonally regulated is 
found to be decreased in breast cancer (Jeng et al, 1993). Cyclins which play important 
roles in different cell cycle checkpoints are studied in breast cancer. Cyclin D1 which 
regulates the Gl-S transition, is shown to be overexpressed in breast cancer (Musgrove 
etal, 1991).
The programmed cell death, apoptosis, is an important physiological defense mechanism 
of cells to avoid cancer. The proto-oncogene, bcl-2, which functions to suppress 
apoptosis is found to be overexpressed in 30-45% of breast cancer cases (Johnston et al, 
1994). Another proto-oncogene, c-myc, is also found to be overexpressed in breast 
cancer (Pavelic etal, 1992).
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1.4.2.2. Gerinline Mutations in Breast Cancer
The search for reliable genetic markers for the susceptibility to develop breast cancer has 
proven to be difficult, since the disease itself is not due to a single gene mutation and 
even the predisposition can be based on different gene defects. There are several tumor 
suppressor genes associated with several syndromes that are thought to be involved in 
genetic predisposition to breast cancer.
I.4.2.2.I. Li-Fraumeni Syndrome (p53)
This rare dominantly inherited cancer syndrome is characterized by a predisposition to 
sarcomas, breast cancer, brain tumors, leukemia and adrenocortical carcinoma in 
children and young adults. Approximately 50% of the women with the Li-Fraumeni 
syndrome may develop breast cancer. Germ-line mutations found in the p53 tumor 
suppressor gene explains this disorder (Malkin et al, 1990). However, it has been shown 
that less then 1% of the women who develop breast cancer at a very young age carry a 
germ-line mutation in the p53 tumor suppressor gene (Borresen et al, 1992)
I.4.2.2.2. Lynch Type II Syndrome (M LHl)
The Lynch type II syndome is associated with a dominantly inherited susceptibility to a 
variety of tumors including breast, colon, uterine and ovarian cancers and melanomas. 
The risk of developing breast cancer is increased in individuals from families with the
19
Lynch type II syndrome, and the relative risk for breast cancer in first-degree relatives 
of index cases identified because of colon cancer has been estimated to be about 5% 
(Krainer, 1994).
L4.2.2.3. Ataxia Teleangiectasia (ATM)
It has been suggested that heterozygotes for the gene for ataxia teleangiectasia (A'l) may 
represent a large proportion of those at high risk for breast cancer, since the relative risk 
for breast cancer in A T  heterozygotes is said to be between 7% and 15%, and the 
heterozygote frequency is estimated to be 1.4%. However, a linkage to the locus in 
familial breast cancer could not be found (Wooster, ei al, 1993).
I.4.2.2.4. Cowden Disease (PTEN)
Cowden disease (CD) is an autosomal dominant syndrome characterized by the 
development of hamartomas in multiple organ systems, and an increased risk of 
developing breast and thyroid cancers. The CD locus was mapped to chromosome 
10q22-23 in 1996 (Nelen, ei al, 1997). Two groups independently identified a tumor 
suppressor gene (PTEN) at 10q23 using loss of heterozygosity analysis in glioblostoma 
multiforme (Steck ei al, 1997; Li el al, 1997). Mutations in this gene were found in 
primary gliomas and carcinomas of the breast and kidney as well as in related cell lines. 
Subsequently, mutations in PTEN  have been identified in multiple CD kindreds 
identifying PTEN  as the gene responsible for CD when mutated. So far no germ-line
2 0
mutations in breast cancer families have been identified. These data provide strong 
evidence that PTEN does not account for hereditary breast cancer susceptibility outside 
of families that are affected by CD. Finally, somatic mutations in primary breast 
cancer specimens have been identified only very rarely (Rhei el al, 1997, Teng, et al, 
1997).
I.4.2.2.5. Genetic Polymorphisms
Environmental contaminants have potential to influence breast cancer risk. The most 
v/ell-defined environmental risk factors are radiation exposure and alcohol ingestion. 
Diet is clearly related to the increased incidence of breast cancer in developed countries, 
but its precise role is not yet established. Epidemiologic and écologie investigations 
must take into account the very complex etiology of breast cancer, and the knowledge 
that tumorigenesis can arise from different mechanisms. Genetic polymorphisms exist in 
genes that govern capacity to metabolize environmental contaminants. Higher risk may 
occur among persons whose enzymes either are more active in the production of 
procarcinogens or fail to detoxify carcinogenic intermediates formed from chemicals in 
the environment (Wolff and Weston, 1997).
Catechol-O-methyltransferase (COMT) participates in the metabolism of potentially 
harmful estrogen metabolites. In a nested case-control study, the low activity COMT 
allele was not strongly associated with breast cancer overall, but was associated with 
increased risk among postmenopausal women, particularly those with higher body mass 
index. A second study also showed no association between the low activity COMT allele
2 1
and breast cancer overall, but it was associated with decreased risk among 
postmenopausal women, and increased risk among premenopausal women in the study 
(Thompson a/, 1998).
The results of a nested case-control study showed a strong association between putative 
high risk genotypes for three of the glutathione S-transferases (GiST^), which act to 
detoxify carcinogens. Women with all three hypothesized high risk genotypes were over 
three times more likely to develop breast cancer than women with all three putative low 
risk genotypes (Gharrier et al, 1999). Other studies, however, did not observe significant 
associations between breast cancer and the GSTMl positive or GSTMl null genotypes 
(Ambrosone a/, 1999).
The CYP17 gene may influence the risk of breast cancer by influencing estradiol 
production. In a case-control study, little association was present between CYP17 
polymorphisms and breast cancer overall but the presence of an A2 allele was associated 
with a 2.5-fold excess risk among women with advanced stage disease (Haiman et al,
1999).
Slow and rapid acetylator individuals exist in most human populations, and the 
mutations responsible for the slow-acetylator genotype have been determined. Slow 
acetylators, is at higher risk of developing breast cancer, and fast acetylators, have an 
increased risk of developing colon cancer (Rodrigo et al, 1999). Previous findings 
suggested that cigarette smoking was a risk factor for postmenopausal breast cancer
2 2
among women with the N-acetyltransferase 2 slow acetylation genotype (Zheng et al, 
1999).
Besides all of these genetic factors that are supposed to be involved in genetic 
predisposition to breast cancer, it has been found that two genes are acting a major role 
in familial breast cancer.
1.5. Hereditary Breast Cancer Genes
Most genetic changes arise spontaneously (sporadic mutations) and are not inherited 
from either parent. Familial and hereditary are terms that refer to increased cancer risk 
within families; however, they are not synonymous. Familial cancer is defined as the 
simple clustering of disease within families. Hereditary cancer is a more specific term, 
referring to a subtype of familial disease with a pattern of distribution consistent with 
Mendelian inheritance of a susceptibility gene. Families in which the predisposition for 
malignant disorders appears to be restricted to breast cancer are known as “breast 
specific” families. There are also families with an increased risk for ovarian cancer 
along with breast cancer. Furthermore, there is evidence that these families show a 
higher incidence of prostate, colon and pancreas cancer (Krainer, 1994). Women are not 
all at equal risk for contracting breast cancer. The most important factor other than age 
that determines who will and who will not manifest breast cancer is the family history of 
breast and related cancers. Descriptive studies of pedigrees of breast cancer-prone 
families and epidemiologic studies of breast cancer in the general population are the 
keys to identifying differences in cancer susceptibility. Since Paul Broca’s report, where
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he described four generations of breast cancer in his wife’s family, an enormous number 
of breast cancer-prone families have been reported. Usually the pattern of breast cancer 
occurrences in these families is most consistent with an autosomal dominant mode of 
inheritance (Lynch, etal, 1994).
1.5.1 Breast Cancer susceptibility gene 1 (BRCAl)
1.5.1.1 Identification of BRCAl
Description of families with multiple cases of breast cancer has led the researchers to 
hunt for a breast cancer susceptibility genes. Linkage analysis allows the localization of 
human disease genes in families with high incidence of the disease. This analysis relies 
on the identification of one or more markers in the genome that segregate with the 
disease. In 1990, Hall et al., made a genetic analysis on 23 extended families with 146 
cases of breast cancer. These families share the epidemiological features that are 
characteristic of familial, versus sporadic, breast cancer: younger age at diagnosis, 
frequent bilateral disease, and more frequent occurrence of disease among men. The 
result of this study showed that familial breast cancer is linked to 17q21 (Hall, et al,
1990) . Several confirmations of this result were subsequently published. After the first 
confirmation by Narod and his coworkers in 1991 (Narod, et al. 1991) this breast- 
ovarian cancer locus has been formally labelled ''BRCAl” (Solomon and Ledbetter,
1991) . Then a third confirming report came from Breast Cancer Linkage Consortium for 
the locus on 17q21 (Easton, et al, 1993).
24
After the localization of BRCAl to 17q21, great efforts were made to identify the gene, 
its transcript, and protein. Miki and his coworkers developed a detailed map of 
transcripts for the 600 kb region of 17q21 between D17S1321 and D17S1325 (Figure 3). 
Sixty-five candidate expressed sequences within this region were identified. Three 
expressed sequences eventually were merged into a single transcription unit whose 
characteristics strongly suggest that it is BRCAl. Conceptual translation of the cDNA 
revealed a single, long open reading frame encoding a protein of 1863 amino acids. 
Homology searches revealed that the protein contains a zinc finger domain in its amino 
terminus. Probing of genomic DNA samples from different species with B R C A l 
sequences revealed strong hybridizations in tissues from humans, mice, rats, rabbits, 
sheep, and pigs. In the same study of Miki and co-workers an 11 bp deletion, a 1 bp 
insertion, a nonsense, a missense and a regulatory mutation that were segregating with 
breast cancer in families linked to 17q21 were identified (Miki Y. et al, 1994).
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Figure 3· Chromosomal location and exonic organisation of BRCAl 
* adapted from NCBI database
**adapted from Breast Cancer Information Core database
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BRCA] appeared to encode a tumor suppressor protein. In order for BRCAl to be a 
tumor suppressor gene it must bear the most important characteristic of a tumour 
suppressor. That is BRCAl protein should be present in normal breast and ovarian tissue 
and should be altered, reduced or absent in breast and ovarian tumors to fulfill the loss- 
of-function characteristic of a tumor suppressor gene. After the localization of BRCAl to 
17q21 many research groups studied whether BRCAl has this characteristic or not, by 
loss of heterozygosity studies (Smith, ei al, 1992; Lindblom, el al, 1993; Cornelis, el al, 
1993; Neuhausen, el al, 1994). Just six months before the identification of BRCAl it was 
shown that transfer of an intact human chromosome 17 led a breast cancer cell line 
(MDA-MB-231) to loose its capacity to induce tumors in nude mice. This result 
obtained from one clone (MDA-231/H17) which bears the long arm of chromosomel7, 
indicated that at least one gene mapping to this region could be a tumor suppressor, 
confirming the BRCAl identification and LOH studies (Negrini, elxtl, 1994). Another 
study by Rao and co-workers also provided evidence for the tumor suppressive effect of 
BRCAl. In this report, it is stated that antisense RNA to BRCAl transforms mouse 
fibroblasts (Rao, etal, 1996).
I.5.I.2. The Function of BRCAl
After the identification of BRCAl and definition of a zinc finger motif in its amino 
terminus in 1994, it is thought that the gene product is a tumor suppressor that may be a 
transcription factor (Miki, el al, 1994). Until 1996 there was no definite evidence about
2 6
the function of BRCAl protein. That year two successive reports stated that the carboxy­
terminal of the protein (nt 1528-1863) bears a transcriptional activation function 
(Chapman and Verma, 1996; Monteiro, et al, 1996).
A very exciting finding appeared in 1996 by Jensen et al, stating that BRCAl is actually 
a protein that is secreted, and exhibited properties of a granin. This result was relied on 
homology search and immunological studies. This was a very important finding because 
BRCAl would be the first secreted tumor suppressor protein (Jensen, et al, 1996). But 
four months later a report by Wilson et al discussed the specificity of the antibody used 
in this paper, and found out that the detected protein was actually EGFR but not BRCAl 
(Wilson e/a/, 1996).
Gudas and co-workers found that BRCAl mRNA and protein levels are regulated by the 
steroid hormones and progesterone (Gudas, et al, 1995). Later, another group has 
suggested iheX BRCAl expression is not directly responsive to estrogen but it is induced 
as a result of the mitogenic activity of estrogen in estrogen receptor positive cells 
(Marks, etal, 1997).
Experimental inhibition of BRCAl expression with antisense oligonucleotides produced 
accelerated growth of normal and malignant mammary cells, but had no effect on non­
mammary epithelial cells (Thompson, et al, 1995). It was also shown that retroviral 
transfer of the wild-type BRCAl gene inhibits in vitro growth of all breast and ovarian 
cancer cell lines tested (Holt, et al, 1996). An evidence on how BRCAl mediate growth 
regulation and tumor suppression came from the report stating that B R C A l
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transactivated expression of cyclin-dependent kinase inhibitor p21 in a /?53-independent 
manner, and that B R C A l  inhibits cell-cycle progression into the S-phase 
(Somasundaram et al, 1997). There is also a report on the induction of apoptosis by 
BRCAl (Shao etal, 1996).
Little is known about the role of BRCAl in human development. But there are several 
studies on the role of BRCAl in mice development. These results suggest that BRCAl is 
crucial in the embriyonic development and that BRCAl homozygous mutants were not 
able to survive (Liu et al, 1996; Lane et al, 1995, Gowen et al, 1996). It is also found 
ihniBRCAl is expressed in rapidly proliferating cell types undergoing differentiation. In 
the mammary gland, BRCAl expression is induced during puberty, pregnancy, and 
following treatment of ovariectomized animals with estrogen and progesterone (Marquis 
et al, 1995). The role of BRCAl in human development remains unclear. There is one 
report on a human BRCAl gene knockout. The reported case was a women who had 
breast cancer diagnosed at age 32 (Boyd et al, 1995). This data implies that the role of 
BRCAl in human development is not as crucial as in mice development or BRCAl 
mutations’ penetrance are rather wide.
It was in 1994 just before the publication of BRCAl identification in a review Vogelstein 
and Kinzler stated some predictions on the possible functions of BRCAl protein. There 
they suggested that BRCAl gene product was part of a repair or replication complex that 
only indirectly affects the growth of breast cancer cells in a similar way to the mismatch 
repair genes (Kinzler and Vogelstein, 1994). Their predictions were actually confirmed 
by several different studies. First report has come from Scully and his coworkers noting
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that BRCAl is associated with RadSl, a protein that functions in DNA double stranded 
break repair, in mitotic and meiotic cells (Scully et al, 1997). In a following report, 
Scully and his coworkers stated that BRCAl is a component of the RNA polymerase II 
holoenzyme, linking BRCAl with the transcription process (Scully ei al, 1997). The 
finding of BRCT module (BRCAl C-terminus) has emphasized the potential importance 
of the BR.CA1 C-terrninal region for BRCAl-mediated breast cancer suppression, as this 
domain showed similarities with the C-terminal regions of a p53-binding protein 
(53BP1), the yeast RAD9 protein involved in DNA repair.
Another evidence confirming and supporting the function of BRCAl in DNA repair and 
transcription process came from Gowen and co-workers stating that mouse embryonic 
stem cells deficient in BRCAl are defective in the ability to carry out transcription- 
coupled repair of oxidative DNA damage, and are hypersensitive to ionizing radiation 
and hydrogen peroxide (Gowen ei al, 1997). A more precise evidence that links BRCAl 
to transcription process noted that BRCAl protein is linked to the RNA polymerase II 
holoenzyme complex via RNA helicase A (Anderson ei al, 1998). The most recent 
evidence that supports the role of BRCAl protein in DNA repair shows that BRCAl 
interacts in vitro and in vivo with hRadSO, which forms a complex with hM rell and 
p95/nibrin. Upon irradiation, BRCAl was detected in discrete foci in the nucleus, which 
colocalize with hRadSO. Formation of irradiation-induced foci positive for BRCAl, 
hRadSO, hMrel 1, or p95 dramatically reduced in HCC/1937 breast cancer cells carrying 
a homozygous mutation in BRCAl but was restored by transfection of wild-type BRCAl 
(Zhongeia/, 1999).
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The important function of BRCAl defined in DNA repair puts it in a crucial role as a 
caretaker gene. This finding lead to the studies that search its relation with the genome 
guardian, p53. It was shown that BRCAl physically associates with p53 and stimulates 
its transcriptional activity. BRCAl and p53 cooperatively induce apoptosis of cancer 
cells indicating that they may coordinately regulate gene expression in their role as 
tumor suppressors (Zhang ei al, 1998; Ouchi et al, 1998). It was also found that breast 
tumors with mutant alleles of BRCAl show high frequency of p53 mutations (Glebov, 
1994). This finding is attributed to its role in DNA repair implying a mutator phenotype 
to BRCAl associated breast tumors. Although this finding is supported by a study 
demonstrating that disruption of BRCAl causes genetic instability and triggers further 
alterations, including the inactivation of p53, that lead to tumour formation (Xu et al, 
1999). Another study shows that the correlation between BRCAl and p53 is not because 
of the attributed role to BRCAl as a mutator, but to multiple mechanisms (Crook et al,
1998). Another finding suggested that BRCAl and BRCAl respond to DNA damaging 
agents, regulated by a p53-sensitive component (Andres etal, 1998).
It is found that in sporadic breast cancer cells 5’ aberrant méthylation of BRCAl CpG 
island leads to decrease in BRCAl mRNA suggesting a mechanism of BRCAl repression 
in sporadic breast cancer (Rice et al, 1998).
I.5.I.3. Mutations in BRCAl
Demonstration of germ-line mutations that disrupt the function of BRCAl protein was 
cmcial to establish primary involvement of this gene in hereditary breast cancer. The
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first publication identifying BRCAl on 17q21 spanning to 100 kb region on the genomic 
DNA, encoding a protein of 1863 amino acids, reported also the first mutations that 
were actually disrupting the function of BRCAl, thus segregating with hereditary breast 
cancer (Miki et al, 1994). This initial report was followed by many studies on BRCAl 
mutation status of several populations and patient groups. To date 697 distinct 
mutations, polymorphisms, and variants have been reported 2887 times.
The mutation data collected in Breast Information Core shows several different pictures. 
Frameshift and nonsense mutations that result in truncated gene product covers 53% of 
all the identified mutations in BRCAl (Figure 4.). The second and third important points 
are related to the status of exon 11. Mutations found in exon 11 constitutes 53% of the 
total number of recorded mutations in BRCAl. Besides 68% of the mutations found in 
exon 11 result in premature stop codon formation. The number of frameshift and 
nonsense mutations found in exon 11 are nearly twice that of the remaining exons 
(Figure 5.)
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Figure 4. Mutation type ratio in BRCAl (adapted from Bic)
Most of the mutations are reported more than once. If the data is reanalyzed based on the 
total number of entries of a mutation, exon 11 re-emerges as the leading region of 
mutations in BRCAl.
Besides these frameshift, nonsense, missense mutations, unclassified variants and 
polymorphisms caused by small changes on DNA sequence, several reports of 
rearrangements mediated by Alu repeats, causing big deletions and duplications have 
appeared (Swensen et al, 1997; Puget et al, 1997; Puget et al, 1999a; Puget et al, 1999b, 
Mazoyer and BRCAl exon 13 dup. Scr. Gr., 2000).
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Figure 5. Frequency of mutation types in BRCAI exon 11 (adapted from Bic)
Population studies on BRCAI mutation status reflects an interesting view on population 
dynamics. The studies on families with three or more cases of female breast and/or 
ovarian cancer shows a picture with wide variations. In this group of patients which is 
constituted from the most susceptible individuals to breast cancer, the mutation 
frequency of BRCAI differs from 79% in Russia (Gayther et al, 1997) to 9% in Iceland 
(Thorlacius ei al, 1996). The mutation frequencies obtained from different populations 
(Britain, Canada, France, Finland , France, Germany, Holland and Belgium, Hungary, 
Iceland, Israel, Italy, Japan, Norway, Russia, Sweden and Denmark, United States) are 
summarized in figure 7.
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Figure 6. BRCAl mutation frequency in different populations in families with three 
or more cases of female breast and/or ovarian cancer (Adapted from Szabo and 
King, 1997)
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Figure 7. BRCAl mutation frequency in US, Hungarian and Icelandic families with 
male and female breast cancer.
(Adapted from Szabo and King, 1997)
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In some of the populations families with male and female breast cancer and patients 
without a family history were studied. The data obtained from these studies are 
summarized in figure 7 and figure 8 respectively.
Italy Israel Japan
Figure 8. BRCAl mutation frequency in Italian, Israeli and Japanese population in 
br east and/or ovarian cancer patients not selected for family history.
(Adapted from Szabo and King, 1997)
These population data clearly show that BRCAl mutations play an important role in 
hereditary breast and/or ovarian cancer cases, although the frequency of mutations vary 
widely in different populations. However in families with male breast cancer exist, and 
in breast and/or ovarian cancer cases without a family history the mutation ratio of 
BRCAl decreases. Mutations in BRCAl occur in approximately 5% of women in whom 
ovarian cancer is diagnosed before the age of 70 years (Stratton et al, 1997)
35
Approximately 85% of breast cancer cases are sporadic and the remaining cases are 
hereditary. From the above mentioned population data it is possible to conclude that 
approximately 30% of hereditary breast cancer cases are linked to BRCAL Thus there 
should be other loci that must be responsible for the remaining 70% of hereditary breast 
cancer cases. Four years after the localization of BRCAl to 17q21 the second breast 
cancer susceptibility gene appeared on the scene.
1.5.2. Breast Cancer susceptibility gene 2 (BRCA2)
I.5.2.I. Identification of BRCA2
In a collaborative study genomic linkage search was performed using 15 families that 
had multiple cases of early-onset breast cancer and that were not linked to BRCAl. 
These families were classified according to the number of cases of female breast cancer, 
male breast cancer, and ovarian cancer. This analysis localized the second breast cancer 
susceptibility locus, BRCA2, to a 6 centimorgan interval on chromosome 13ql2-13 
(Wooster ei al, 1994). Just a few months later it was shown that the wild type allele of 
BRCA2 was lost in breast cancers from families linked to chromosome 13ql2-13, 
confirming the role of that locus in hereditary breast cancer (Collins et al, 1995).
A year later, BRCA2 gene was identified with a cDNA of 10400 bp and 27 exons (Figure 
9). In that study six germline mutations, each causing serious a disruption to the open 
reading frame of the transcriptional unit, in breast cancer families were reported 
indicating that this was the BRCA2 gene (Wooster et al, 1995).
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Figure 9. Chromosomal location* and exonic organization of BRCA2**.
* adapted from NCBI database.
**adapted from Bic database.
Ovarian cancer occurrence in the family along with breast cancer is an important point 
that links the breast cancer susceptibility to BRCAl (Miki et al. 1994). For BRCA2, the 
presence of male breast cancer in the family is one of the most important determining 
characteristic of hereditary breast cancer linkage to BRCA2 fThorlacius et al, 1995). 
Breast cancer is a rare disease in men, affecting less than 0.1% of the male population 
(Haraldsson et al, 1998). The expression of hormone receptors in male breast tumors 
suggested a central role for endogenous hormones in male breast carcinoma. High 
degree of androgen receptor was detected. The high frequency of bcl-2 positivity may 
implicate antiapoptotic mechanisms in the carcinogenesis of male breast cancer. 
Besides, positive cyclin D1 expression is associated with increased PFS (progression
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free survival) in male breast cancer cases, which suggested that interactions among cell 
cycle regulatory proteins might be important in this disease (Rayson et al, 1998).
In a recent study genomic alterations of sporadic and BRCA2 positive male breast cancer 
tumors were compared to those of female tumors. The results suggested that despite 
substantial hormonal differences between females and males, similar genetic changes 
were occuring during tumor progression. Besides, the presence of a highly penetrant 
germline BRCA2 mutation apparently leads to a characteristic somatic tumor progression 
pathway, again shared between affected male and female mutation carriers (Tirkkonen et 
al, 1999). Analysis of the expression of BRCAl and BRCA2 genes in ovariectomized 
mice progesterone, shows the up-regulation of mRNA expression in the breast by 
ovarian hormones significantly greater for BRCAl than for BRCA2. This result suggest 
that the phenotype difference associated with germ-line mutations in these genes is 
related to the differential regulation of these genes by sex hormones (Rajan etal, 1997).
BRCA2 mutations is also important in pancreatic cancer. It is reported that in 41 
pancreatic cancer cases not selected on the basis of family history, 5% of cases bear a 
BRCA2 mutation. In the same report this ratio was determined as 10% for Jewish 
pancreatic cancer cases. According to statistical formulas it is calculated that having a 
BRCA2 mutation leads to an increase of 3.51 fold in pancreatic cancer, 2.59 fold in 
stomach cancer, 4.97 fold increase in gall bladder and bile duct cancers, in 2.58 fold 
increase in malignant melanoma, and in 4.65 fold increase in prostate cancer (Ôzçelik, et 
al, 1997).
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I.5.2.2. The Function of BRCA2
The first report about the function of BRCA2 was about its expression through cell cycle. 
It was found that like BRCAl, BRCA2 mRNA levels was at a maximum level during late 
Go and S phases implicating its protective role in cellular proliferation (Vaughn, et al, 
1996; Wang étal, 1997; Su étal, 1998).
Later it was shown that BRCA2 exon 3 sequences (residues 18-105) had a transcription 
activation potential (Milner et al, 1997). It was also found that BRCAl had a histone 
acetyl transferase activity. This result supports the previous report since there were some 
findings implying a possible relationship between gene transcriptional activation and 
histone acetylation by several enzymes involved in acetylation and deacetylation of 
histone residues (Siddique etal, 1998).
In an other study by Sharan and co-workers it was found that like BRCAl, BRCAl plays 
a role in DNA repair. Their results indicated that BRCAl interacts with DNA-repair 
protein RadSl in mouse. The BRCAl deficient embryos showed developmental arrest 
and they were radiation sensitive. These observations along with the finding of Brca2 
interaction with RadSl explains tumor-suppressor function of BRCAl (Sharan et al, 
1997). A report that supported this finding stated that mice bearing BRCAl mutations in 
homozygous state may survive but they have a wide range of defects, including small 
size, improper differentiation of tissues, absence of germ cells, and the development of 
lethal thymic lymphomas. They also showed that fibroblasts cultured from these 
embryos have a proliferation defect which can be explained by the over-expression of
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p53 and p21 (Connor et al, 1997). These results which show the loss of p53 checkpoint 
caused by the defected through its role in DNA repair, clearly illustrate the gatekeeper 
and caretaker model explaining tumorigenesis.
1.5.2.3. Mutations in BBCA2
BRCA2 as BRCAl is a gigantic gene and the mutations are scattered along the gene. To 
date a total of 642 mutations have been reported for 1702 times. Approximately 50% of 
the mutations are frameshift and nonsense mutations resulting in a truncated product 
(Figure 10). Exon 11 constitutes approximately 60% of the gene and nearly 50% of the 
mutations in BRCA2 resides in this exon (Breast Information Core). The mutation ratio 
of exon 11, according to mutation types compared to other exons is shown in figure 11.
BRCA2 mutation status was studied in different patient groups and different populations. 
These data revealed that BRCA2 mutations are responsible for approximately 30% of all 
hereditary breast cancer cases. The results show variations among different populations. 
These variations are clearly seen in figure 12.
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Figure 11. Frequency of mutations according to type in BRCA2 exon 11.
(Adapted from Bic)
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BRCA2 mutation status variation reflects an interesting picture presenting Iceland with a 
more than 60% mutation frequency. A founder mutation plays an important role in 
breast cancer cases in Iceland. A five base-pair deletion in exon 9 of the BRCA2 gene, 
999deI5, is detected in 0.6% of the population, in 7.7% of female breast cancer patients, 
and in 40% of males with breast cancer. Prostate and pancreatic cancer are seen in 
carriers of this mutation (Thorlacius et al, 1996; 1997). However in Finland, BRCA2 
mutation frequency was found to be only 8%. This was explained by low frequency of 
male breast cancer seen in Finland. Male breast cancer represents only 0.5% of all breast 
cancers detected in this country. In this study it is also found that BRCA2 mutations were 
identified more frequently both in families with four or more cases of breast cancer an in 
families with both breast and ovarian cancer (See Figure 12) (Vehmanen, et al, 1997).
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Figure 12. BRCA2 mutation frequency in English, Canadian, Finnish, French, 
Hungarian, Icelandic, Swedish, Danish, and US populations in families with three 
or more cases of female breast and/or ovarian cancer.
(Summarized from Szabo and King, 1997)
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BRCA2 mutations were found to be important in male breast cancer cases. In a study 
performed in Sweden, it was found that 21% of male breast cancer cases without a 
family history bear a BRCA2 mutation (Haroldsson, et al. 1998). Different results were 
obtained from two independent studies carried out in US. In the study of Friedman et al, 
it was found that only 4% of male breast cancer cases were detected with a BRCA2 
mutation. Besides, only the cases carrying BRCA2 mutation had a family history of 
cancer. Furthermore, 89% of male breast cancers with a family history of breast/ovarian 
cancer in first-degree relatives remain unaccounted for by mutations in either the BRCAl 
or the BRCA2 gene (Friedman, et al, 1997). Whereas in the other study, it was found that 
14% of male breast cancer cases bear a BRCA2 mutation. Besides, this ratio increase to 
85% in cases with a family history of breast cancer, either male or female (Couch, et al, 
1996). However, BRCAl mutations were also found in male breast cancer cases 
(Struewing, et a/, 1995). The mutation status of BRCA2 in families with male breast 
cancer is shown in figure 13. The mutation status of BRCA2 in breast and/or ovarian 
cancer patients not selected for family history in Icelandic, Israeli and Japanese 
populations is summarized in figure 14.
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Figure 14. BRCA2 mutation frequency in breast and/or ovarian cancer patients not 
selected for fam ily history from Icelandic, Israeli and Japanese populations
(Summarized from Szabo and King, 1997)
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BRCA2 mutation status was also studied in sporadic breast and ovarian cancer cases. In a 
study by Lancaster et al, it was found that only in 2.8% of breast and ovarian cancer 
cases a BRCA2 mutation is detected (Lancaster, et al, 1996). This study and the data 
summarized in figure 15 show that BRCA2 is an infrequent target for somatic 
inactivation in breast and ovarian carcinomas, similar to the results obtained ioxBRCAl.
Conflicting results were obtained from two studies dealing with the role of BRCA2 
mutations in pancreatic cancer in view of frequent losses of heterozygosity on 
chromosome 13ql2-13. In the study by Teng et al BRCA2 mutation was found in 
pancreatic cancer (Teng et al, 1996) whereas in another study by Katagiri and his 
coworkers, it was found that BRCA2 mutations do not play a role in pancreatic cancer 
but do play a role in liver carcinogenesis (Katagiri et al, 1996).
Big rearrangements were also documented in BRCA2 as in BRCAl. A deletion of 5068 
base-pairs disrupting exon 3 which encodes the transcription activation domain of 
BRCA2 gene was identified in a Swedish breast /ovarian cancer family (Nordling et al,
1998) . A similar deletion disrupting amino-terminal transactivation domain was found in 
50% of RER+ (replication errors) endometrial tumors, indicating that somatic mutations 
in BRCA2 may confer a growth advantage in RER+ endometrial carcinomas (Koul et al,
1999) .
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In a study by Mazoyer and her coworkers a substitution at nucleotide 3326 causing to a 
stop codon was identified. This stop codon resulting in the loss of the final 93 amino 
acids is found to be polymorphic (Mazoyer ei al, 1996). This interesting finding shows 
how variable a mutation’s penetrance can be.
A similar finding implying a mutator phenotype in BRCA2 associated tumors shows 
high frequency of p53 mutations (Gretarsdottir, et al, 1998). This finding, although not 
confirmed, indicates presence of a mechanism other than mutator phenotype attributed 
to BRCA2 associated tumors by Crook and coworkers (Crook et al, 1998).
1.5.3. Penetrance and Histoprognosis of BRCAl and BRCA2 genes
Accumulation of somatic genetic changes during tumor progression may follow a unique 
pathway in individuals genetically predisposed lo cancer, especially by iho. BRCAl gene. 
Activation or loss of genes in the affected chromosomal regions may be selected for 
during tumor progression in cells lacking functional BRCAl or BRCA2 (Tirkkonen et al, 
1997).
It was found that truncating mutations clustered in a region of approximately 3.3 kb in 
exon 11 are correlated with the highest risk of ovarian cancer relative to breast cancer 
(Gayther a/, 1997)
The estimated cumulative risk of breast cancer reached 28% by age 50 years and 84%
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by age 70 years in women. The corresponding ovarian cancer risks were 0.4% by age 
50 years and 27% by age 70 years. The lifetime risk of breast cancer appears similar to 
the risk in BRCAl carriers, but there was some suggestion of a lower risk in BRCA2 
carriers <50 years of age (Ford et al, 1998).
When compared with non-hereditary breast cancers, BRCAl associated breast cancer 
presents a higher percentage of advers pathobiological features such as grade 3, 
aneuploidy, aneuploid tumor with S phase, estrogen and progesterone receptor 
negativity (Watson et al, 1998). The histology of breast cancers in predisposed women 
differs from that in sporadic cases, and there are differences between breast cancers in 
carriers of BRCAl and BRCA2 mutations. This results suggest that breast cancer due to 
BRCAl has a different natural history to BRCA2 or apparently sporadic disease, which 
may have implications for screening and management (Breast Ca. Link. Con., 1997).
Several studies showed that the proportion of families not linked to BRCAl or to BRCA2 
may be higher than previously expected suggesting the existence of at least one more 
major breast cancer-susceptibility gene (Sobol el. a/, 1994; Serova ei al, 1997). The 
attribution of approximately 60% of hereditary breast cancer cases to BRC Al and 
BRCA2 gene lead to the studies currently in progress to identify the third locus.
1.5.4. Breast Cancer Susceptibility Genes and Risk Assesment
The observation of familial cancer syndromes opened up the possibility to make risk 
assesment for individuals from these families. Approximately 10% of ovarian cancer
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cases and 7% of breast cancer cases in the general population are estimated to be 
hereditary (Claus et al, 1996). The identification of BRCAl mABRCA2 genes, which 
together are thought to be responsible for nearly 60% of hereditary breast cancer cases 
(Miki et al 1994; Wooster et al, 1995), makes possible to define a mutation in one of 
these two genes segregating with the disease, in a breast cancer family, and to give 
genetic counseling for an unaffected individual. Although the possibility of making a 
prediction on cancer susceptibility, especially about a cancer which is the leading cause 
of deaths from cancer between ages 15 and 54 in women, is very exciting, the issue must 
be considered with care and caution.
Different mutations will confer different risks for breast cancer, ovarian cancer, and 
other cancers. Different mutations confer different likelihoods of tumor types and age of 
onset. Even the same mutations in the BRCAl and BRCA2 genes confer different risks 
on different patient populations. It must be concluded that there are substantial 
modifying factors such as genetic, dietary, hormonal which affect the likelihood of a 
given BRCAl or BRCA2 mutation causing cancer. Penetrance of a mutation is a very 
important issue in risk evaluation. Because of just a few mutations Ashkenazi Jewish 
and Icelandic populations are ideal models for such studies.
Three founder mutations have been described in Ashkenazi Jewish breast cancer 
families: 185delAG and 5382insC in BRCAl, and 6174delT in BRCA2 (Simard et al, 
1994; Friedman et al, 1995; Neuhausen et al, 1996). One of these mutations was found 
in 31% of Ashkenazi women with early-onset (<42 years of age) breast cancer, and
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41% of Ashkenazi women with a positive family history who were diagnosed with 
breast cancer at 42-50 years of age (Neuhaussen et al. 1996; Oddoux et al, 1996; Offit et 
al, 1996). In a series of 220 North American Ashkenazi breast cancer families, one of 
the founder mutations accounted for 45% of all families, and for a significantly higher 
percentage (73%) of families with a history of ovarian cancer (Tonin et al, 1996). The 
combined population frequency of these mutations in a number of large series of young 
Ashkenazi controls approaches 2.5% in total; BRCAl 185delAG, 1%; BRCAl 5382insC, 
0.1%; and BRCA2 6174delT, 1.4% (Streiwithg et al, 1995; Oddoux et al, 1996; Roa at 
al, 1996). Current estimates of penetrance of these mutations are based on the high-risk 
pedigrees used in the original linkage studies, where lifetime penetrance of BRCAl 
mutations was found to be >80% for breast cancer, and approached to 50% for ovarian 
cancer (Easton et al, 1993; Ford et al, 1994; Friedman et al, 1995). Penetrance of 
BRCA2 mutations was estimated to be similar for breast cancer, and approached to 50% 
for ovarian cancer (Wooster et al, 1994). Families used in these studies were selected for 
the presence of at least four affected living relatives (for high penetrance at an early 
age), so it is not appropriate to apply these penetrance estimates to families with fewer 
affected individuals or to asymptomatic carriers without family history (Levy-Lahad et 
al, 1997).
Actually, Û\q BRCA2 6174delT mutation has been inferred to have lower penetrance 
than the BRCAl 185delAG mutation, because, although their frequencies in the 
Ashkenazi population are similar, BRCA2 6174delT is significantly less common in 
high-risk Ashkenazi breast-ovarian cancer families. Comparisons of these frequencies
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have led to the conclusion that BRCA2 6174delT penetrance is 25-30% that of BRCAl 
185delAG (Oddoux et al, 1996; Roa et al, 1996). Thus, genetic testing is technically 
more feasible in the setting of a limited number of mutations in a defined ethnic group. 
However, before such testing is implemented, either in affected individuals or in the 
population, it is important to define the penetrance and attributable risk of these 
mutations for breast and ovarian cancer in the population studied (Levy-Lahad et al, 
1997).
In a similar study performed in Iceland 10.4% of women and 13% of men diagnosed 
with breast cancer unselected for family history were found to carry 999del5 mutation. 
This mutation is present in around 0.6% of the Icelandic population. The estimated risk 
of breast cancer at age 50 for female carriers of this mutation was found to be 17% and 
37.2% at age 70 (Thorlacius etal, 1998).
Overall, at present, it is thought that a woman carrying a gene mutation in BRCAl has a 
56% risk of developing breast cancer by age 70, and a 16.5% risk of developing ovarian 
cancer. Higher estimates of up to 80% lifetime risk have been reported in some series. 
Reasons for these differences include the severity of penetrance in the distinct high-risk 
families that have been studied, and the technical limits of genetic analysis that may 
inaccurately represent the extent of BRCA mutation (Weber, 1998-online coverage). In a 
study by Couch and coworkers it was found that among women with breast cancer and a 
family history of the disease, the percentage of BRCAl coding-region mutations is less 
than 45% predicted by genetic-linkage analysis. BRCAl mutations were identified in
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16% of women with a family history of breast cancer. Only 7% of women from families 
with a history of breast cancer but not ovarian cancer had BRCAl mutations. The rates 
were higher among women from families with a history of both breast and ovarian 
cancer (Couch et al, 1997). Analyzing all of these results shows that genetic counseling
for hereditary breast cancer is an issue that should be evaluated carefully.
1.5.5. Homozygous germ-line mutations
Heterozygous germ-line mutations in tumor suppressor genes are associated with 
hereditary cancer such as /?55 in Li Fraumeni syndrome, BRCAl and BRCA2 in 
hereditary breast cancer, RB  in retinoblastoma and M L H 1 in HNPCC. Since 
homozygous germ-line tumor suppressor mutations are rare its phenotypic consequences 
have not been studied thoroughly.
There is one report on a human BRCAl gene knockout. The reported case was a women 
who had breast cancer diagnosed at age 32 and her mother and four of her maternal 
aunts had breast and/or ovarian cancer. She also has a first cousin on her paternal side of 
the family who was diagnosed with ovarian cancer at age 22. Sequencing analysis 
revealed that she had a deletion of two A nucleotides at position 2800, resulting in an in- 
frame stop codon at nucleotide 2820. This homozygous allele encodes a 900 amino acid 
protein (Boyd ei al, 1995). This data implies that the role of B R C A l in human 
development is not as crucial as in mice development or BRCAl mutations’ penetrance 
are rather wide. Whereas homozygous germ-line BRCAl mutations do not change the
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disease phenotype, homozygous inheritence of another hreditary cancer syndrome gene, 
MLHl, results in a different disease spectrum.Two recent reports identified human 
MLHl deficiency in two unrelated families (Ricciardone et al, 1999; Wang et al, 1999). 
These MLHl deficient cases developed hematological malignancy at a very early age 
and displayed signs of neurofibromatosis type 1. These studies implies that a 
homozygous MLHl mutation and consequent mismatch repair deficiency results in a 
mutator phenotype characterized by leukemia or lymphoma associated with 
neurofibromatosis type 1.
1.6. Mutation Screening
BRCAl and BRCA2, responsible for breast cancer susceptibility, are gigantic genes 
spanning over 80 and 100 kb genomic DNA regions. They have 5500 bp and 10400 bp 
cDNAs respectively, and have many mutations scattered on the entire gene. This makes 
the mutation screening of these genes a very tedious task. To detect the mutations in a 
most effective and cost efficient way, an appropriate screening methodology should be 
chosen. Since direct sequencing is not a suitable methodology for screening, a sensitive 
and cost effective indirect mutation detection technique is needed. An ideal mutation 
screening method should :
2. screen a region up to 1 kb.
3. be 100% sensitive.
4. not give false positives and false negatives.
5. not have more than one step.
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6. not need expensive equipments.
7. should not contain the usage of biohazardous reagents.
8. should not need electrophoresis.
9. should be performed in short time.
10. should be cheap.
To date, no mutation screening technique bearing all of these character!ctics has been 
defined Many research laboratories have developed and adopted different 
methodologies for the screening of breast cancer susceptibility genes. The commonly 
used techniques used in the screening of BRCAl and BRCA2 are protein truncation test 
(PTT), denaturing gradient gel electrophoresis (DGGE), denaturing high performance 
liquid chromatography (DHPLC), single strand conformation polymorphism (SSCP), 
heteroduplex analysis (HA), and direct sequencing (DS).
1.6.1. Protein Truncation Test
The protein truncation test (PTT) is a mutation detection method that specifically detects 
mutations, which lead to the termination of translation and subsequent protein 
truncation. Since nonsense and frameshift mutations cause premature protein products 
and are very frequently seen in BRCAl and BRCA2 genes, PTT is one of the most 
popular screening techniques (Maugard et a/, 1998).
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Figure 16. Schematic representation of protein truncation test.
In this method cDNA or large genomic exons are amplified via PCR using a forward 
primer carrying at its 5’ end a T7 promoter, followed by a eukaryotic translation 
initiation sequence (Kozak sequence) which includes an ATG start codon. This way a 
synthetic transcription unit is obtained. The amplification product is then added to an in 
vitro transcription-translation system, which includes all the necessary components for 
the transcription and translation processes. For the detection of the end product, a 
labelled (radioactively, or colorimetric. Biotin) amino acid (methionine) is added to 
the reaction.
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The end product is then loaded to a SDS-PAGE along with a protein molecular weight 
marker. If the size of the product is lower than expected, the amplified area is sequenced 
to identify the mutation.
PIT  ignores missense mutations; thus polymorphisms detected by other methods (SSCP, 
HA) do not need to be excluded as disease causing alterations by sequencing. PTT 
allows the analysis of large stretches of coding sequences (at least 3 kb, for example 
entire exon 11 of BRCAl. In addition to these advantages, one should consider that PTT 
does not locate a mutation precisely. It is restricted to truncating mutations. It is 
important to note that PTT is only suitable for large exons, unless RNA extraction and 
cDNA preparations are done (http://www.ich.ucl.ac. uk./cmgs/ptt98.htm).
1.6.2. Denaturing Gradient Gel Electrophoresis (DGGE)
The two strands of a DNA molecule separate, or melt, when heat or a chemical 
dénaturant is applied. The temperature at which a DNA duplex melts is influenced by 
two factors;
1. The hydrogen bonds formed between complimentary base pairs, GC rich regions melt 
at higher temperatures than regions that are AT rich.
2. The attraction between neighbouring bases of the same strand or “stacking”.
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When double-stranded DNA is electrophoresed into a gradient of increasing dénaturant a 
portion of a given strand separates but the strands are anchored together by the portion 
(higher melting domain) which has not melted at this point. This split in the duplex 
suddenly arrests the movement of the molecule in the gel. If a single-base change is 
present in a similar duplex in the split portion, the dénaturant concentration for strand 
separation is usually different, thus the arrest of movement occurs at a different position 
in the gel, and a mutation can be detected by the differential positions of arrest (Cotton, 
1993). Complete strand separation is prevented by the presence of a high melting 
domain, which is usually artificially created at one end of the molecule by incorporation 
of a GC clamp, accomplished during PCR amplification using a PCR primer with a 5’ 
tail consisting of a sequence of 40 GC.
DGGE has a high mutation detection rate and sensitivity. It is a non radioactive method, 
and PCR fragments may be isolated from the gel to use in sequencing reactions. But 
genes which are exceptionally GC rich are not easily analyzed by DGGE. The use of 
special GC clamped primers is another limiting factor in this technique 
fhttp://www.ich.ucl.ac.ulc/cmgs/mutdet.htm).
1.6.3. Denaturing High Performance Liquid Chromatography (DHPLC)
This method is a modified version of heteroduplex analysis. Dénaturation of PCR 
product causes to the separation of two alleles. Renaturation by cooling the product 
leads to random annealing of the two alleles. If an individual is heterozygous for a
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mutation, heteroduplexes will form between wild-type and mutant alleles along with 
homoduplexes. These homoduplexes and heteroduplexes migrate differently in a gel 
matrix. In DHPLC, these products are run in partially denaturing conditions to 
exaggerate the difference between two species. The detection is performed by an HPLC 
system linked to a computer. The mutation detection rate of this method is close to 
100%, but it needs expensive equipment. Although single base mutations have been 
detected in 1.5 kb fragments, maximum sensitivity is achieved with fragments of 150- 
450 bp (http://www.ich.ucl.ac.uk/cmgs/mutdet.html
1.6.4. Single Strand Confirmation Polymorphism (SSCP)
SSCP is the simplest and most commonly used method of mutation detection. PCR is 
used to amplify the region of interest and the resultant DNA is separated as single 
stranded molecules by electrophoresis in a non-denaturing polyacrylamide gel. A strand 
of single-stranded DNA folds differently from another if it differs by a singly base, and 
it is believed that mutation-induced changes of tertiary structure of the DNA results in 
different mobilities for the two strands. These mutations are detected as the appearance 
of new bands on autoradiograms (radioactive detection), by silver staining of bands or 
by the use of fluorescent PCR primers which are subsequently detected with an 
automated DNA sequencer (non-radioactive detection).
The tertiary structure of single stranded DNA changes under different physical 
conditions such as temperature and ionic environment. Hence the sensitivity of SSCP
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depends on these conditions. While some empirical rules have emerged for the choice of 
separation conditions for sequence variants in particular sequence contexts, it is not 
possible to predict whether a mutation can be detected under given conditions, especially 
when the mutation is in a new sequence context. Mutation detection for PCR-SSCP is 
generally over 80% in a single run for fragments shorter than 300 bp 
(http://www.ich.ucl.ac.uk/cmgs/mutdet.htmy
1.6.5. Heteroduplex Analysis (HA)
Heteroduplex is double-stranded DNA in which the two DNA strands do not show 
perfect base complementarity. When DNA is denatured, the two strands are separated. 
On renaturation or annealing, complimentary DNA strands reassociate and form a 
homoduplex. However, when there is a mutation in one of the strands then a 
heteroduplex is formed. The electrophoretic mobility of heteroduplex in non denaturing 
polyacrylamide gel is less than that of homoduplex, and they can be detected as extra 
slow moving bands. Resolution is better in specially formulated gel matrice (MDE). In 
fragments of under 200 bp insertions, deletion and most single base substitutions are 
detected. Several mutations in a gene can also be combined to form a multiplex 
heteroduplex analysis (http://www.ich.ucl.ac.uk/cmgs/mutdet.html.
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Figure 17. Comparison of SSCP, DGGE and HA in mutation detection.
1.6.6. Direct Sequencing
Dideoxy chain termination DNA sequencing method involves the in-vitro synthesis of a 
DNA strand by a DNA polymerase using a specifically primed single-stranded DNA 
template. DNA synthesis is carried out in two steps. The first is the labeling step in 
which the primer is extended using limiting concentrations of the deoxynucleoside
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triphosphates, including radioactively labeled dATP. This step continues to complete 
incorporation of labeled nucleotide into DNA chains. These initial primer extensions are 
distributed randomly in length from several nucleotides to hundreds of nucleotides. In 
the second step, the concentration of all the deoxynucleoside triphosphates is increased 
and a chain-terminating nucleotide analog is added. These 2’3’-dideoxynucleoside-5’- 
triphosphates lack the 3’OH group necessary for DNA chain elongation. Processive 
DNA synthesis occurs, with extensions on the average of only several dozen 
nucleotides, until all growing chains are terminated by a ddNTP. When proper mixtures 
of dNTPs and one of the four ddNTPs are used, enzyme-catalyzed polymerization will 
be terminated in a fraction of the population of chains at each site where the ddNTP can 
be incorporated. Four separate reactions, each with a different ddNTP give complete 
sequence information (Sambrook et al. 1989). The reactions are then loaded on a 
denaturing polyacrylamide gel which is able to differentiate one base pair difference. 
The visualization is done by autoradiography which shows a ladder like picture 
containing the sequence information of the nucleotides.
In automated DNA sequencing, the principle of the reaction is also based on dideoxy 
chain termination reaction, but fluorescent detection is used instead of radioactive 
detection. Fluorescence gives the advantage of using different colors for each ddNTP 
thus the possibility of setting up one reaction instead of four in dye terminator chemistry. 
In the alternative dye primer chemistr>', the fluorescent dye is on the primers used for 
sequencing. So in this way, four reactions must be set up. However, the advantage of
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fluorescence in both cases is that the samples are loaded into one lane, since the labels of 
the fragments are different.
In automated DNA sequencing, in order to increase the amount of the product, the 
reaction is set up by cycle sequencing. In this PCR like process, repeated cycles of 
thermal dénaturation, primer annealing, and polymerization to produce greater amounts 
of product is used .
The sequencing products are detected either on a polyacrylamide gel or capillary 
electrophoresis which has a laser detector that emits fluorescence and sends the obtained 
data to a collection software on a computer. The collected raw data is then analyzed by 
an analysis software translating this raw data to sequence data (PE, 1995.1). To date the 
golden standard of mutation detection and the most efficient tool of genome projects is 
DNA sequencing. Though the detection rate of DNA sequencing is given as 100%, to be 
sure of a mutation two strands of the analyzed region should be sequenced (PE, 1995.2).
61
2. MATERIALS AND METHODS
2.1. Materials
2.1.1. Families
2.1.1.1. Hereditary Breast Cancer Families
Six families are classified as hereditary breast cancer families according to the presence 
of at least two affected first degree relatives.
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Figuréis. Pedigrees of the hereditary breast cancer group. Age of the individuals are 
indicated below the symbols, the age at diagnosis of the affected individuals are 
indicated in parenthesis. Abbreviations indicated by symbols are as follows: Br.breast, 
Br & Ov: breast and ovarian, C: colon, E: endometrial, G: gall bladder, L; leukemia, Lg: 
lung, Li; liver, Ov; ovarian, S; stomach.
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2.1.1.2. Familial.Breast Cancer Families
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Br
Figure 19, Pedigrees o f the familial breast cancer group. Age of tnc nidividuals are 
indicated below the symbols, the age at diagnosis of the affected individuals are 
indicated in parenthesis. Abbreviations indicated by symbols are as follows: Br:breast, 
Br & Ov: breast and ovarian, C: colon, E; endometrial, G: gall bladder, L: leukemia, Lg: 
lung, Li: liver, Ov: ovarian, S: stomach.
2.1.2. Oligonucleotides
Oligonucleotides used in polymerase chain reactions and cycle sequencing reactions 
v.'ere synthesized on the Beckman Oligo lOOOM DNA synthesizer (Beckman 
Instruments Inc., Fullerton, CA, USA) at Bilkent University, Faculty of Science, 
Department of Molecular Biology and Genetics. The nucleotide sequences of the 
primers used for the amplification and sequencing of the BRCAl and BRCA2 genes are 
given in Table 4 and 5
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Table 4. BRCAl Primer sequences, expected fragments’ sizes and optimal [MgCh]
Exon Primer
name
Primer sequence Expected
Size
( b p )
[Mgcy
(mM)
1 1 AF 5'-GGAATTAAATGAAAGAGTATGAGC-3' 470 2
AR 5'-CTTCCAGCCCATCTGTTATGTTG-3’
1 1 BF 5'- GCTGCTTGTGAATnrCTGAGACGGATG-3' 445 2
BR 5'-ATCCAAGGAACATCTTCAGTATCTCTAGG-3’
1 1 CF 5’-CCATGCTCAGAGAATCCTAG-3' 425 2
CR 5’-GGCTCAGTAACAAATGCTCC-3’
1 1 DF 5'-TATGCCTGGTAGAAGACTTCCTCC-3' 480 2
DR 5'-TTGGGAAAACCTATCGGAA-3'
1 1 EF 5'-AACGAAAGCTGAACCTATAAGCAGC-3' 450 3
ER 5'-TCTTCTCTTGGAAGGCTAGGATTG-3’
1 1 FF 5’-GTGTTAAATACCAGTGAACTTA-3' 422 3
FR 5’-TrC A CnTCrrC CA nTCTA TG C -3'
1 1 GF 5'-TCCATrGGGACATGAAGTTAACC-3' 310 2
GR 5'-TGACCAACCACAGGAAAGCCTG-3'
1 1 HF 5’-CAAGCCTGTACAGACAGTTAATATCAC-3’ 420 2
HR 5-GGAGCCCACTTCATTAGTAC-3’
1 1 IF 5’-CCAAGTACAGTGAGCACAATTA-3’ 415 2
IR 5'-ATCATCTAACAGGTCATCAGGT-3’
1 1 JF 5’-GGAAGTAGTCATGCATGCATCTCAGGT-3' 400 2
JR 5’-GCTATrCTTCAATGATAATAAATrCTCC-3’
1 1 KF 5-CGTTGCTACCGAGTGTCTGTCTAAG-3’ 450 2
KR 5'-GTGCTCCCAAAAGCATAAA-3'
2 2F 5'-GAAGTTGTCAnTrATAAACCnr-3’ 250 3
2R 5’-TGTCTnTCTTCCCTAGTATGT-3'
5 5F 5'-CTCTTAAGGGCAGrrGTGAG-3' 200 2
5R 5’-TrCCTACTGTGGTTGCTrCC-3'
13 13F 5'-AATGGAAAGCTTCTCAAAGTA-3’ 259 2
13R 5’-TGTTGGAGCTAGGTCCTrAC-3’
20 20F 5’-ATATGACGTGTCTGCTCCAC-3' 220 2
20R 5'-GGGAATCCAAATTACACAGC-3’
24 24F 5’-ATGAATTGACACTAATCTCTGC-3’ 275 2
24R 5’-GTAGCCAGGACAGTAGAAGGA-3’
PTTl llA F 5  ’ - g g a t c c t a a t a c g a c t c a c t a t a g g g a g a c c a c c a t g g C T G 3000 1.5
1 CTTGTG A A TnrCTG -3 ’
llA R 5 ’ -G ACGTCCTAGCTGTGTG AAG-3 ’
6 6
Table 5. BRCA2 Primer sequences, expected fragments’ sizes and optimal [MgCli]
i Exon Primer
Name
Primer Sequence Expected 
Size (bp)
[MgClJ
(mM)
11 aF 5'-САТГСАТСОТАСПТААТПТОТСАС-3’ 1156 1.5
aR 5'-CCTCC AAAACTGTGATrTGAAATTG-3 ’
11 bF 5'-CCTCCAAAACTGTGATTTGAAATTG-3' 1162 1.5
bR 5'-ССТАААССССАСТТСАГПТСАТС-3'
11 cF 5’-TGGCArrAGATAATCAAAAGAAACTG-3’ 1534 1.5
cR 5'-TGATGGCTAAAACTGGTGAnTCAC-3’
11 (IF 5’-TGCGAAAGGTCAAGAAGCATG-3’ 931 1.5
dR 5-GGTGAAGAGCTAGTCACAAGTrCCTC-3’
11 eF 5’-CTrATTCAGTCATrGAAAATTCAGCC-3' 782 1.5
eR 5’-AAACCTTATGTGAATGCGTGCTAC-3'
11 IF 5’-GCCAGTATTGAAGAATGTTGAAGATC-3’ 1253 1.5
fr 5'-CCAGCTCACAAGAGAAGAAAATACTG-3’
11 gf 5’-GCnTCCACrrGCTGTACTAAATCC-3’ 899 1.5
gd 5'-ACAGATTCTAAACTGCCAAGTCATG-3’
11 IF 5’-GATGGTACnT.\ATnTGTCACTrTG-3' 220 3
IR 5’-TTCCTTATrACATTTTGCrrCTTrAT-3'
11 2F 5'-CTAGCTCTnTGGGACAATTCTGAGG-3' 300 3
2R 5'-'TTTCATGATCATATAAAAGAAT-3'
11 3F 5’-CAAAAGTGGAATACAGTGATAC-3' 250 3
3R 5’-ATAATnTCATrTAAAGCACATACAT-3'
11 4F 5'-TCTAGAGGCAAAGAATCATA-3' 305 3
4R 5’-TCATrGTCTGAGAAAAGTTC-3’
11 5F 5’-TTCAAAAATAACTGTCAATCC-3' 230 2
5R 5-GTTGCTTGnTATCACCTGT-3’
11 6F 5’-AACCCATTTl’CAAGAACTCTACCA-3’ 274 3
6R 5’-CTGAAGCTACCTCCAAAACTGTG-3’
11 7F 5 ’ -AC AAATGGGCAGG ACTCTTAGG-3’ 300 3
7R 5’-CCTGCTTGGAAAATAACATCTG-3'
11 8F 5’-AGTrGTTTCTGATrGTAAAAATAGTC-3' 310 3
8R 5'-GCTGCTGTCTACCTGACCAA-3'
11 9F 5’-GATGCTGATCTTCATGTCATAA-3' 300 3
9R 5’-TACCTCTGCAGAAGTTTCCTCACTA-3'
11 lOF 5'-GGGnTAGGGGCnTTATTC-3' 237 3
lOR 5'-TA TCA G TTG G CA rrTA rrA rm T-3'
11 IIF 5’-CTrCAAGTAAATGTCATGATTCTGTC-3’ 202 3
HR 5’-CTGGCAGCAGTATAnTGTTATCT-3'
11 12F 5’-ATrACTGAAAATTACAAGAGAAATA-3’ 244 3
12R 5'-AAAAAGTTAAATCTGACTCAAATCT-3'
11 13F 5 , nTATGAAGGAGGGAAACACTCA-3’ 282 3
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13R 5'-TTCAGAATTTAAGGAAAAGTTATGC-3'
11 14F 5'-AAAAATATTAGTGTCGCCAAAGAG-3’ 278 2
14R 5’-TGTATGAAAACCCAACAGAGTAGG-3’
11 15F 5’-GTTAAACACAAAATACTGAAAG-3' 233 3
15R 5'-CATTGATGGCTAAAACTGGTG-3'
11 16F 5’-TCATCAAGCTAGCGGAAAAA-3’ 265 2
16R 5'-TGGCACCACAGTCTCAATAG-3'
11 17F 5'-CTGCCCCAAAGTGTAAAGAAAT-3’ 230 2
17R 5’-AATGACTGAATAAGGGGACTGAT-3'
11 18F 5’-GTCCTGCAACTTGTTACAC-3’ 230 2
18R 5’-G A m T T G T C A m T C A G C -3’
11 19F 5’-AACCAGAAAGAATAAATACT-3’ 334 3
19R 5'-TCCTCAACGCAAATATCTTCAT-3'
11 20F 5’-TTTCCAAAGTAATATCCAATGTA-3' 291 3
20R 5’-ATmTGATTrATrCTCGTTGTT-3'
11 21F 5'-AAGACATATTTACAGACAGT-3’ 300 3
21R 5’-TG.\AGCTrCCCTATACTACAT-3’
11 22F 5’-CACCTTGlGATGTTAGnTG-3' 350 3
22R 5'-TrGGGAATATAAATGTTCTGGAGTA-3'
11 23F 5'-A AAGTAACGAAC ATrCAGACCA-3’ 310 2
23R 5'-CTGGGTTTCTCTTATCAACCGA-3’
11 24F 5'-AGTCTTCACTATTCACCTACG-3' 280 3
24R 5’-GTGAGACTrTGGTTCCTAAT-3'
11 25F 5’-TTCAACAAGACAAACAACAGT-3' 270 3
25R 5’-TGTCAGTTCATCATCTTCCATAAA-3'
11 26F 5’-TrACTCCAAAGATrCAGAAAACTAC-3’ 290 3
26R 5'-AGCATACCAAGTCTACTGAATAAAC-3'
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2.1.3. Chemicals and Reagents
Acetic acid Carlo Erba, Milano, Italy N64197
Acrylamide Sigma, St Louis, MO, USA A9099
Agarose Basica LE, EU 031217PR
Ampicilline Boehringer Mainheim 85454021
APS Carlo Erba, Milano, Italy 7727-54-0
Bacto Agar Difco, Michigan, USA 0140-01
Bactotryptone Difco, Michigan, USA 0123-173
Bacto-yeast extract Difco, Michigan, USA 0127-17-9
Bis-acrylamide Aldrich 14607-2
Boric acid Sigma, St. Louis, MO, USA B0252
Bromophenol blue Sigma, St. Louis, MO, USA B5525
CaCl2 Sigma, St. Louis,MO, USA C3306
Chloroform Carlo Erba, Milano, Italy 334353
Genetic Analyzer Buf. PE, Applied Bio. CA, USA 402824
EcoRI Sigma, St. Louis, MO, USA R6265
EDTA pH 8.0 Carlo Erba, Milano, Italy, 303201
Ficoll type 400 Sigma, St. Louis, MO, USA F4375
Glucose Sigma, St. Louis, MO, USA G7021
IPTG MBI Fermentas R0392
isoamyl alcohol Merck, Schuchardt, Germany K25713595 842
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Kacetate
M ets 35
Merck, Schuchardt, Germany K24483720 
Amersham UK SJ 1015
NaCl Carlo Erba, Milano, Italy, 479687
NaOH Carlo Erba, Milano, Italy 480507
dATP 10 mCi/ml Amersham UK A 0005
Phenol
POP6
Proteinase K 
SDS
Sigma, St Louis, MO, USA P1037/ 
PE, Applied Bio. CA, USA 9903020 
Appligene, MD, USA 130203
Merk, Schuchardt, Germany D822050
Sodium Acetate Merk, Schuchardt, Germany TA6555468 
TNT T7 coupled reticulocyte lysate system Promega, L4610
TrisHCl
trisodium citrate
TSR
Urea
XGal
Xylene cyanol
Merk, Schuchardt, Germany K21570697 627 
Sigma, St. Louis, MO, USA S4641 
PE, Applied Bio. CA, USA 401674 
Merck, Schuchardt, Germany, K22063886 
Sigma, St. Louis, MO, USA B4252 
Sigma, St. Louis, MO, USA X4126
2.1.4. PCR Materials
Taq Polymerase 5U/|li1 (MBI Fermentas Inc, Amherst, NY, USA) 
25 mM MgCla
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lOX Taq Polymerase buffer (100 mM TrisHCl, pH 8.8, 500 mM KCl, 0.8% Nonidet 
P40)
10 mM dNTP (10 |iM each of dATP, dCTP, dGTP, dTTP)
0.2 ml Theimowell tubes Corning Costar Corp, Cambridge, MA, England 
Gene Amp PCR system 9600 Perkin Elmer, Foster City, CA, USA
2.1.5. Sequencing Materials
ABI PRISM Ready Reaction Dye Terminator Cycle Sequencing Kit (ABI. Perkin 
Elmer, Foster City, CA, USA) containing terminator premix with A-dye terminator, C- 
dye terminator, G-dye terminator and T-dye terminator; dlTP, dATP, dCTP and dTTP; 
Tris-HCl (pH 9.0); MgCl2; thermal stable pyrophosphatase; and AmpliTaq DNA 
polymerase, FS (8 U/|Ltl).
Thermo Sequenase Dye Terminator Cycle Sequencing Pre-Mix Kit (Amersham Life 
Science, Inc., Cleveland, OH, USA) containing 125 mM Tris HCl, pH 9.5, 5 mM 
MgCk, 1.25 mM dITP, 0.25 M dATP, dCTP, dTTP, ddATP (dye-labeled), ddCTP (dye- 
labeled), ddGTP (dye-labeled), ddTTP (dye-labeled). Thermo Sequenase DNA 
polymerase. Thermoplasma acidophilam thermostable inorganic pyrophosphatase 
(TAP), Nonidet P40, Tween 20, 6.25% glycerol.
ART PRISM*  ^BigPye™ Terminator Cycle Sequencing Ready Reaction kit (ABI, Perkin 
Elmer, Foster City, CA, USA) containing A-DyeTerminator labeled with dichloro R6G, 
C-Dye Terminator labeled with dichloro ROX, G-Dye Terminator labeled with dichloro
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RllO, T-Dye Terminator labeled with dichloro TAMRA, dATP, dCTP, dITP, dUTP, 
AmpliTaq DNA polymerase, FS, with thermally stable pyrophosphatase, MgCl2, Tris 
HCl buffer, pH 9.0.
0.2 ml Thermowell tubes Coming Costar Corp, Cambridge, MA, England 
Gene Amp PCR system 9600 Perkin Elmer, Foster City, CA, USA
377 Automated Sequencer ABI, Perkin Elmer, Foster City, CA, USA
310 Genetic Analyzer ABI, Perkin Elmer, Foster City, CA, USA
41cm green labeled capillaries
2.1.6. Standard Solutions and Buffers
20XSSC
3 M NaCl
0.3 M Trisodium citrate
(Sterilized by autoclaving)
Extraction buffer 
10 mM
10 mM
0.5%
TrisHCl pH 8.0 
EDTA pH 8.0 
SDS
Proteinase K 20 mg/ml
Phenol/chloroform/isoamyl alcohol 25:24:1
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PTT Stop solution
1/JO 2b mercaptoethanol in 2X Laemlli
Sodium Acetate (NaOAc) 3M pH 5.2
lOX TBE
108 g Tris HCl
55 g boric acid
20 ml 0.5 M EDTA
lOX Protein Buffer
144 g Glycine
250 ml Tris IM pH 8.3
10 ml 10% SDS (filtered)
Complete final volume to 1 It with ddH20 .
2X Laemlli
4 ml 10% SDS (filtered)
2 ml Glycerol
1.2 ml Tris IM pH Ó.8-7.4
2.8 ml ddH20
10 ml 0.01% Bromphenol
6X Loading buffer
15% Ficoll type 400
0.05% Bromophenol blue
0.05% Xylene cyanol
LB medium
10 g Bactotryptone
5g Bacto-yeast extract
lOg NaCl
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950 ml ddH,0
The solutes are dissolved by shaking. The pH is adjusted to 7.0 with 5N NaOH (0.2ml). 
The volume of the solution is completed to 1 It with deionized H2O. LB medium is 
sterilized by autoclaving.
LB-Agar
10 g
5g
10 g
15 g
Tryptone 
Yeast extract 
NaCl
Bacto Agar
The solutes are dissolved in deionized water with a total volume of 1 It. The solution is 
sterilized by autoclaving. 1 ml of ampicilline is added when its temperature decreases to 
50°C.
1 M  CaC/2
10 ml aliquots is kept at -20°C. When preparing competent cells, an aliquot is thawed 
and diluted to 100 ml with deionized water. The solution is sterilized by filtration 
through a 45 |im illter and chilled to 0°C before using.
lOG mg/ml Ampicilline is prepared and sterilized by filtrating through a 45 |Lim filter. The 
solution is aliquotted in 1.7 ml tubes and stored at -20°C.
IPTG
solution is prepared in a concentration of 0.2 M.
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XGal
solution is prepared in a concentration of 50 ing/mi.
GTE
50 mM Glucose
25 mM TrisCl (pH 8.0)
10 mM EDTA
The solution is autoclaved for sterilization and stored at 4°C.
Solution II
0.2 N 
1%
NaOH (It is freshly diluted from a ION stock) 
SDS
Solution III
60 ml 5 M Kacetate
11.5 ml Acetic acid
28.5 ml deionized water is mixed to prepare solution III. This solution is tored at 4°C.
Phenol/Chloroform 1:1
40% (39:1) Acrylamide:bis-acrylamide
39 g Acrylamide
Ig Bis-acrylamide
Dissolve in ddH20, complete the final volume to 100 ml with ddH20. Filter and degas.
20% (19:1) Acrylamide: Bisacrylamide:
19 g Acrylamide
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Ig Bis-acrylamide
Dissolve in ddHiO, complete the final volume to 100 ml with ddH20. Filter and degas.
40% (29:1) Acrylamide: Bisacrylamide
29 g Acrylamide
1 g Bis-acrylamide
Dissolve in ddH20, complete the final volume to 75 ml with ddH20. Filter and degas.
2.2. Methods
2.2.1.DNA isolation from peripheral blood
Blood can be stored at 4”C for a maximum of five days before aliquoting and freezing. It 
is frozen in 700 |il aliquots. After thawing blood add 800 |xl of IXSSC, mix by 
vortexing and spin at 13000 rpm for 1 minute. Remove thel .4 ml supernatant, discard 
into disinfectant (Chlorox). It is important not to disturb the cell pellet at this step. Add 
1.4 ml of IXSSC, briefly vortex, and spin at 13000 rpm for 1 minute. Remove all the 
supernatant avoiding the pellet. For cell lysis add 800 pi of extraction buffer and 10 pi 
of proteinase K. Briefly vortex and incubate the sample at 56°C for 3 hours. At the end 
of the incubation period, if  the cell pellet is totally dissolved, add 400 p i 
phenol/chlorofbrm/isoamyl alcohol (25:24:1) and vortex for 1 minute. This step must be 
carried out in a fume hood. The sample is then centrifuged for 5 minutes at maximum 
speed. Remove the upper aqueous layer and place in a new tube. Repeat 
phenol/chloroform/isoamyl alcohol extraction step till the interface becomes clear. After
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the final extraction the upper aqueous layer (700 |il) is divided into two tubes. Then add 
35 |o.l 3 M, NaOAc (pH 5.2), and 700 |il ice cold absolute ethanol into each tube. Mix 
the tubes by inversing and place at -20°C for 30 minutes. Spin the samples for 15 
minutes at maximum speed, remove the alcohol and wash the pellet with 1 ml of 70% 
ethanol at room temperature. After 5 minutes of spin at 13000 rpm, remove ethanol with 
a micropipette. Leave the tubes open in the fume hood to evaporate the remaining 
ethanol. The DNA pellet can be resolubilized in 200 |xl of sterile deionized water and 
incubated overnight at 56®C. The quality and concentration of DNA samples are 
determined by optical density measurement and by agarose gel electrophoresis.
2.2.2. Agarose Gel Electrophoresis
Agarose gel electrophoresis is a commonly used method for DNA analysis. The method 
is based on the mobility of DNA molecules in the pores of agarose, an algue derived 
polymer, which is dependent on the shape and weight of DNA, and also the current 
applied during electrophoresis and the concentration of agarose gel.
Genomic DNA samples and PCR products are routinely analyzed by agarose gel 
electrophoresis. Agarose gels are prepared with IXTBE. They contain 1 |il of Ethidium 
bromide solution (20 mg/ml). 2 |il of genomic DNA sample with 6X loading buffer is 
loaded on 1% agarose whereas 5 pi of PCR product in 6X loading buffer is loaded on 
2% agarose gel. Runs are performed with IX TBE at 90 V for 30 minutes.
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2.2.3. Polymerase Chain Reaction
Polymerase chain reaction is a method frequently used in the analysis of specific 
nucleotide sequences. PCR amplification involves two oligonucleotide primers that 
flank the DNA fragment to be amplified and repeated cycles of heat dénaturation of the 
DNA, annealing of the primers to their complementary sequences, and extension of the 
annealed primers with heat stable Thermus aquaticus DNA polymerase. Each cycle 
results in the exponential accumulation of the specific target DNA segment, 
approximately 2", where n is the number of cycles (Saiki et al, 1998). In order to amplify 
the desired regions of BRCAl and BRCA2 genes sets of different primer pairs is used. 
The prim.er sequences, expected fragment sizes, and optimal MgCb concentrations are 
summarized in Table 4 and 5.
2.2.3.I. PCR for Heteroduplex amilysis
PCR reactions are carried out in a total of 10 |il. 10 ng of genomic DNA is amplified 
with 2 pmols of forward and reverse primers, 1.5 U Taq Polymerase, IX Taq 
Polymerase buffer, 1 .5-3.0 inM MgCh, 1 |iCi P^  ^ dATP and 200 |xM dNTP. PCR 
conditions are as follows; Initial dénaturation is at 95°C for 5 min. Dénaturation for 30 
seconds at 94“C, annealing 30 sec at 55°C, 40 sec or 1 min 15 sec at 72°C for 
polymerization depending on the length of target fragment is repeated for 30 cycles 
(Except for the fragments of BRC A2 exon 11, 40 sec of extension time is used in the
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amplification process). 10 min at 72°C for final extension is followed by 4°C soak. 
Presence of these radioactively labeled PCR products are not checked on agarose gel 
electrophoresis. They are then loaded on 6% native PAGE PCR products are denatured 
at 95°C for 10 min and left at 37°C for 2 hours for the formation of heteroduplexes.
2.2.3.2. PCR for DNA Sequencing
PCR reactions are carried out in a total volume of 50 fil. 50 ng of genomic DNA is 
amplified with 10 pmol of forward and reverse primers, 1.5 U Taq Polymerase, IX Taq 
Polymerase buffer, 1.5-3.0 mM MgCb and 200 |jM  dNTP. PCR conditions are as 
follows; Initial dénaturation is at 95°C for 5 min. 30 cycles of dénaturation for 30 sec at 
94°C, annealing 30 sec at 55°C, polymerization 40 sec or 1 min 15 seconds depending 
on the length of target fragment. 10 min at 72°C for final extension is followed by 4°C 
soak. PCR products are checked by agarose gel electrophoresis before application of 
PCR purification columns (Qiagen) according to manufacturer’s instructions in order to 
get rid of excess primers, and primer-dimers which may interfere with cycle sequencing. 
2 p.1 of purified PCR products were loaded on 2% agarose gel for concentration 
estimation. A minimum of 40 ng PCR product is required for cycle sequencing.
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2.2.3.3. PCR for PTT
PCR is performed using Expand long template PCR system which contains Taq and Pwo 
DNA polymerases. Tv/o mixes are prepared to prevent primers and DNA polymerases 
from interacting with each other at inappropriate conditions, since Pwo DNA 
polymerase has 3’5’ exonuclease activity.
Mix 1 . 1.4 ^ıldNTP(5mM)
0.8 jj.1 Forward Primer (10 pmol)
0.8 |il Reverse Primer (10 pmol) 
ddH20 to a total volume of 9 |il.
200 ng DNA
Mix 2. 6.3^1 Buffer
0.2 |il DNApol.
ddH20 to a total volume of 8.5 |il. Total PCR volume 20 fxl.
PCR conditions are as follows:
94°C 2 min
94T 10 sec
6 5 ^ 30 sec 10 cycles
68"C 2 min J
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The gel is washed 20 minutes in 10% acetic acid, 20% methanol solution and processed 
30 minutes in Amplify . Dried gel is exposed to X-ray film for 12-18 hours.
2.2.5. Cloning
2.2.5.1.Ligation and Transformation
The frameshift mutations detected by sequencing of PCR products were confirmed by 
cloning the suspected fragment in a TA cloning vector (Promega) and sequencing it. 
PGEM Teasy cloning vector is used according to the manufacturer’s directions. After 
overnight ligation reaction at 4°C, the PCR fragment inserted to the vector is 
transformed to E. coli HBlOlstrain. Transformation is performed as follows: 200 |il of 
HBlOl is incubated overnight in 5 ml of LB. 1.5 ml of grown cells is transferred into a 
1.5 ml tube and spinned for 1 min at 13000 rpm. The supernatant is removed and 500 p.! 
cold CaCb is added. The sample is left on ice for 30 minutes and spinned for 1 min at 
13000 rpm. The supernatant is removed again and this time 100 pbCaCL is added. The 
pellet is dissolved gently by pipetting. The whole ligation product (10 pi) is added on the 
dissolved pelled and incubated on ice for 30 min. The sample is transferred into a 42°C 
water-bath for 90 sec. After a 2 min incubation on ice 1 ml LB is added and left 1 hour 
at 37°C. At the end of this incubation period the sample is centrifuged for 2 min. The 
supernatant is removed leaving 50 pi sample in the tube to dissolve the pellet by 
pipetting.The dissolved pellet is plated out on ampiciline (100 mg/ml) containing and 
Xgal (20 pi 50 mg/ml), IPTG (100 pi 100 rnM) spreaded LB Agar plates and incubated 
overnight at 37°C.
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The vector used in this assay contains the multiple cloning site in the lacZ gene that is 
used to choose the successful ligated product containing clones. The clones which 
contain ligated products will disrupt the lacZ gene so that galactose cannot be used by 
them. They will appear as white. Next day pick up at least 20 white colonies with pipette 
tips, put them in 15 ml LB (containing lOOmg/ml ampicilline) and incubate overnight at 
37°C in order to prepare their low scale DNA samples.
2 .2 .5 .2 .L0W scale DNA Isolation
1.5 ml overnight grown cultures are transferred into 1.7 ml tubes and centrifuged for 3 
min at 13000 rpm. The supernatant is decanted and 100 ці GTE is added on the pellet. 
The pellet is dissolved by vortexing. Freshly prepared 200 |il solution II is added and 
mixed by inverting. 150 |j,l solution is added and mixed by vortexing. At this step the 
cell pellet is lysed and the DNA becomes naked. In order to isolate and purify the DNA, 
phenol/chloroform extraction is performed. 500 |il phenol/chloroform is added and 
vortexed for 2 min. After 5 min centrifugation at 13000 rpm, the aqueous layer is 
transferred in a new tube. This step is repeated till the interface becomes clear. 1 ml cold 
absolute ethanol is added on the aqueous layer transferred into a new tube. The sample is 
mixed by inverting, left for 30 min at - 20°C and centrifuged for 10 min at 13000 rpm. 
The supernatant is poured . The pellet is Avashed with 500 |il 70% ethanol. Ethanol is 
removed and the pellet is air dried. 20 |j.l RNAase (0.1 |ig/|il) containing sterile 
deionized H2O is used to dissolve the pellet.
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2.2.5.3. Restriction Endonuclease Digestion
In order to confirm that the DNA samples isolated from white colonies contain the 
ligated PCR products, the samples were digested with EcoRI. Recognition sites of this 
enzyme resides just at the upstream and downstream points of the ligation products. So 
that the digestion reaction will give two fragments, the linearized vector and the inserted 
PCR fragment. In the case that the PCR fragment does not contain any EcoRI 
recognition site. 2 |o.l (approximately 100 ng) of DNA is incubated for 4 hours at 37“C 
with 1 U EcoRI and lOX buffer in a total of 10 |0,1. The digested product is loaded on 2% 
agarose gel and run with IX TBE for 1 hour at 90 V. The DNA samples containing the 
PCR product are chosen for sequencing.
2.2.6. DNA Sequencing
2.2.6.I. Cycle Sequencing
Shifted fragments in HA are reamplified and sequenced. After PCR amplification, 
products are applied to PCR purification columns (Qiagen), and quantitated on agarose 
gel. 40 ng of PCR product (up to 7 p,!) is mixed with 3.2 pmol forward or reverse primer, 
and 4 pi Ready Reaction Mix. The reaction volume is completed to 20 pi with sterile 
deionized H2O. PCR conditions are as follows: 3 min initial dénaturation at 98°C; 30 
cycles of 10 sec at 96“C, 5 sec at 50°C, and 4 min at 60“C; soak at 4°C.
84
In order to remove unincorporated ddNTPs which may interfere with sequencing 
reactions, samples are precipitated with ethanol. 20 |j,l of total product is added on 68 p.1 
cold absolute ethanol, and 7 1^ 7,5 M ammonium acetate. After vortexing the tube is 
placed on ice for 15 min, and centrifuged at 13000 rpm for 30 min. Supernatant is 
removed, and 250 |il 70% ethanol is added to wash the pellet. An additional 
centrifugation for 5 min is performed. Ethanol is removed and the pellet is air dried in a 
fume hood keeping them in dark. Light may give harm to fluorescein tags in sequencing 
products.
2.2.7. Polyacr3'lamide Gel Electrophoresis (PAGE)
2.2.7.1 PAGE for Heteroduplex Analysis
For HA 6% polyacrylamide is prepared in a total volume of 75 ml with 11.25 ml 40%, 
39:1 acrylamide:bisacrylamide, 7.5 |li1 lOX TBE, 5.3 ml glycerol (7%), 50.5 ml 
deionized H2O 400 jil 10% APS, and 50 |il TEMED. The gel solution is filtered and 
degased before the addition of APS and TEMED. Glass plates are thoroughly washed 
and wiped with distilled water and 70% ethanol before pouring the gel. The poured gel 
is left on bench for 2-5 hours to polymerize.
15 |il of loading buffer is added on PCR products before loading on polyacrylamide gel. 
5 ml of PCR products are loaded on polyacrylamide gel. The gel is run overnight at
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400V. The next day, the gel is dried in a vacuum drier at 80"C for 45 minutes and 
exposed to X Ray film overnight.
2.2.7.2. PAGE for PTT
For PTT 12% polyacrylamide is prepared in a total volume of 7,5 ml with 4,5 ml 40%, 
29:1 aciylamide:bisacrylamide, 1.85 ml TrisHCl 1.5 M, pH 8.8, 3.25 ml deionized H2O, 
75 III 10% SDS, 60 t^l 10?/o APS, and 5 pi TEMED. The gel solution is filtered and 
degas before the addition of APS and TEMED. Glass plates are thoroughly washed and 
wiped with distilled water and 70% ethanol before pouring the gel. The poured gel is left 
on bench for 15 minutes to polymerize. 2 ml of stacking gel with 18 pi 10%APS and 2.5 
pi TEMED is poured on the running gel. The electrophoresis is performed in BIORAD 
protein apparatus with IX protein buffer at 200 V for one hour.
2.2.1.2. Denaturing PAGE for DNA Sequencing
Denaturing PAGE is used for in DNA sequencing to get a resolution of 1 bp difference. 
4% polyacrylamide gel is prepared from 5 ml 20% stock solution of 19:1 
acrylamide;bisacrylamide, 5 ml lOX TBE, 18 g urea , 250 pi 10% APS, 35 ml TEMED 
is added. The volume is brought up to 50 ml with deionized H2O.
The pellet is resuspended in 4 pi ready loading dye, heated to l( fC  for 2-5 minutes and 
placed on ice before loading on polyacrylamide gel. Loading 2 pi of sample is enough
8 6
for PAGE on A BI377 Automated DNA Sequencer. Sequencing data is collected by ABI 
Data Collection 1.0.4 software and analyzed with DNA Sequence Analysis 3.0 software. 
Alignment studies are done with Sequence Navigator software after the reanalysis of the 
data by the Factura program.
2.2.8. Capillary Electrophoresis
DNA sequencing reactions are also analyzed with capillary electrophoresis on ABI 310 
Genetic Analyzer using POP6 and 41cm green labeled capillaries. For capillary 
electrophoresis the pellet is resuspended in 25 p,l of TSR (Template Suppression 
Reagent). The sample is denatured at 95°C for 3 minutes before putting on autosampler 
tray. Sequencing data is collected by ABI Data Collection 1.0.4 software and analyzed 
with DNA Sequence Analysis 3.0 software. Alignment studies are done with Sequence 
Navigator software after the reanalysis of the data by the Factura program.
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3. RESULTS
In this study germ-line BRCAl and/or BRCA2 mutations were screened in 50 breast 
and/or ovarian cancer patients. Selected regions of BRCAl (exons 2 , 5 , 1 1 , 13, 20, 24) 
and BRCAl (exon 1 1 ) were analyzed. Since exon 11 of both genes are too big to analyze 
in a single experiment, BRCAl exon 11 is divided to eleven and BRCAl exon 11 is 
divided to seven overlapping fragments. Both of the genes were first screened by 
heteroduplex analysis which is an indirect mutation screening method. Altered 
fragments were re-amplified and further analyzed by DNA sequencing.
3.L DNA Isolation
Genomic DNA was isolated from patients blood cells using phenol chloroform 
extraction method. Isolated DNA samples were evaluted quantitatively and qualitatively 
by UV spectrophotometry and agarose gel electrophoresis. All DNA samples had a 
260/280 optical density ratio of 1.7-1.8, and showed a single, intact, high molecular 
weight band on agarose gel (Figure 19). The concentrations of these DNA samples are 
200, 180, 210, 260, 195, 230,240 and 245 |ig/ml respectively.
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Figure 19. Analysis of extracted genomic DNA samples.
Samples were electrophoresed in a 0.8% agarose gel at 9V/cm for 45 minutes. Lanes 1, 
96/1; 2, 96/2; 3, 96/3; 3, 96/4; 4, 96/5; 5, 96/6; 6, 96/7; 8, 96/8.
3.2. Polymerase chain reaction
All PCR products were checked by agarose gel electrophoresis. Figure 20 shows the 
amplification products of BRCAl exon IIB  and BRCA2 exon 1 1 -6 . The expected sizes 
of the PCR product was 445 bp and 274 bp respectively, which is confirmed by 
comparison of the observed DNA bands with the size marker.
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.445 bp 
274 bp
Figure 20. Analysis o f PCR products.
PCR products purified from Qiagen PCR purification columns were electrophoresed in a 
2% agarose gel at 9V/cm for 45 minutes. Lanes 1; (j)X174 DNAHinfl marker, 2 : 97/344 
and 3; 97/359 BRCAJ exon 1 IB; 4: 97/544 and 5: 97/545 BRCA2 exon 11-6 .
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3.3. Protein Truncation Test
BRCAl exon 11 of two hereditary (96/1, 96/2), three familial (96/3, 96/4, 97/474) and 
four early onset (96/5, 96/10, 97/344, 97/473) breast cancer cases was analyzed with 
protein truncation test. No altered size fragments were detected in any one of the 
samples. Figure 21 shows the BRCAl exon 11 PTT profile of patients 97/344, 97/473, 
97/474 (lane 1, lane 2 and lane 3 respectively) and control (lane 4) sample.
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Figure 21. PTT oiBRC Al exon 11.
Lanes 1, 97/344; 2 , 97/473; 3, 97/474; 4, control.
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3.4. Heteroduplex analysis
Heteroduplex analysis was performed on EC 160 vertical gel apparatus. Native 39:1 
(6%) polyacrylamide gels were run at 400V overnight at room temperature. Gels were 
dried at 80°C for 45 minutes and exposed to Xray film overnight at -80°C.
3.3.1. BRCAl exon 2
BRCAl exon 2 is amplified with 2F and 2R primers as a fragment of 250 bp. Results of 
one hereditary (97/137; lane 2), four early onset (97/114, 97/270, 97/274, 97/343; lanes 
1, 3, 4, 5 respectively) breast cancer cases, and control (lane 6) sample is shown in 
figure 22. No shifts were observed in any one of the samples.
Figure 22. Heteroduplex analysis of BRCAl exon 2.
Lanes 1, 97/114; 2, 97/137; 3, 97/270; 4, 97/274; 5, 97/343; 6, control.
92
BRCAl exon 5 is amplified with 5F and 5R primers as a fragment of 200 bp. Results of 
four hereditary (96/1, 96/2, 97/544, 97/545; lanes 1, 2, 4, 5 respectively) and two early 
onset (96/10, 97/702; lanes 3 and 6) breast cancer cases, and control (lane 7) sample is 
shown in figure 23. No shifts were observed in any one of the samples.
3.3.2. BRCAl exon 5
5 6 7
s' t
'i:
Figure 23. Heteroduplex analysis of BRCAl exon 5.
Lanes 1, 96/1; 2, 96/2; 3, 96/10; 4, 97/544; 5, 97/545; 6, 97/702; 7, control.
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BRCAl exon 11A is amplified with AF and AR as a fragment of 470 bp. Results of one 
hereditary (97/137; lane 2) and three early onset (97/114, 97/359, 97/472; lanes 1 , 3, 4 
respectively) breast cancer cases and control (lane 5) sample is shown in Figure 24. No 
shifts were observed in any one of the samples.
3.3.3. BRCAl exon 11A
Figure 24. Heteroduplex analysis of BRCAl exon 11 A.
Lanes 1, 97/114; 2, 97/137; 3, 97/359; 4, 97/472; 5, control.
94
BRCAl exon IIB  is amplified with BF and BR as a fragment of 445 bp. Results of a 
familial (97/474; lane 2) and three early onset (97/472, 97/641, 97/656; lanes 1, 3, 4 
respectively) breast cancer cases, and control (lane 5) is shown in figure 25. A 
heteroduplex formation resulting in a shift has been observed in patient 97/641 (lane 3). 
This region of the patient was later reamplified and further analyzed by DNA 
sequencing.
3.3.4. BRCAl exon IIB
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Figure 25. Heteroduplex analysis of BRCAJ exon IIB .
Lanes 1, 97/472; 2, 97/474; 3, 97/641; 4, 97/656; 5, control; Arrow indicates the shifted 
fragment.
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BRCAl exon 1 1 C is amplified with CF and CR as a fragment of 425 bp. Results of four 
early onset (97/661, 97/662, 97/670, 97/674; lanes 1, 2, 3, and 4 respectively) breast 
cancer patients, and control (lane 5) sample is shown in figure 26. No shifts were 
observed in any one of the samples.
Z3.S.BRCA1  exon IIC
Figure 26. Heteroduplex analysis of BRCAl exon IIC .
Lanes 1, 97/661; 2, 97/662; 3, 97/670; 4, 97/674; 5, control.
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BRCAl exon IID  is amplified with DF and DR as a fragment of 480 bp. Results of four 
early onset (97/639, 97/641, 97/655, 97/656; lanes 1, 2, 3, and 4 respectively) breast 
cancer cases, and control (lane 5) sample is shown in figure 27. No shifts were observed 
in any one of samples.
3.3.6. BR CA l exon IID
Figure 27. Heteroduplex analysis of BRCAl exon IID .
Lanes 1, 97/639; 2, 97/641; 3; 97/655; 4, 97/656; 5, control.
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BRCAl exon 1 IE is amplified with primers EF and ER as a fragment of 450 bp. Results 
of six early onset (97/508, 97/639, 97/641, 97/670, 97/674, 97/681; lanes 1, 2, 3, 4, 5, 
and 6) breast cancer cases is shown in figure 28. A band shift has been observed in 
patient 97/670 (lane 4).
3.3.7. BR CA l exon 11 E
1 2 3 5 6
Figure 28. Heteroduplex analysis of BRCAl exon IIF .
Lanes 1, 97/508; 2, 97/639; 3, 97/641; 4, 97/670; 5, 97/674; 6, 97/681; 7, control. Arrow 
indicate the shifted fragment.
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BRCAl exon IIF is amplified with primers FF and FR as a fragment of 422 bp. Result 
of five early onset (96/10, 97/114, 97/270, 97/274; lanes 1, 2, 3, and 4 respectively) 
breast cancer cases, and control (lane 5) sample is shown in figure 29. No shifts were 
obsen'ed in any one of the samples.
3.3.8. exon 1 IF
Figure 29. Heteroduplex analysis of BRCAl exon IIF
Lanes 1, 96/10; 2, 97/114, 3, 97/270; 4, 97/274; 5, control.
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BRCAl exon IIG  was amplified with primers GF and GR as a fragment of 310 bp. 
Results of four early onset (97/343, 97/639, 97/508, 97/662; lanes 1, 2, 3, and 4 
respectively) breast cancer cases, and control (lane 5) is shown in figure 30. A similar 
band shift was observed in two familial (97/475 and 97/702) and in an early onset breast 
cancer case (97/508, lane 3).
3 . 3 . 8 . exon IIG
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Figure 30. Heteroduplex analysis of BRCAl exon IIG .
Lanes 1, 97/343; 2, 97/639; 3, 97/508; 4, 97/662; 5, control. Arrows indicate the shifted 
fragments.
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BRCAl exon IIH  was amplified with primers HF and HR as a fragment of 420 bp. 
Results of two hereditary (96/1, 96/2; lanes 1 and 2), one familial (96/8; lane 3), one 
early onset (96/10; lane 4) breast cancer cases, and control (lane 5) sample is shown in 
figure 31. No shifts were observed in any one of the samples.
3.3.9. BR CA l exon IIH
Figure 31. Heteroduplex analysis of BRCAl exon IIH .
Lanes 1, 96/1; 2, 96/2; 3, 96/8; 4, 96/10; 5, control.
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BRCAl exon 111 is amplified wuth primers IF and IR as a fragment of 415 bp. Results 
of two hereditary (97/544, 97/545; lanes 2 and 3), and three familial (96/8, 97/702, 
98/60; lanes 1, 4, and 5) breast cancer cases, and control (lane 6) is shown in figure 32. 
No shifLs were observed in any one of the samples.
33AQ .BRCA1  exon 111
Figure 32. Heteroduplex analysis of BRCAl exon 111.
Lanes 1, 96/8; 2, 97/544; 3, 97/545; 4, 97/702; 5, 98/60; 6, control.
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BRCAl exon 11J was amplified with primers JF and JR as a fragment of 400 bp. Results 
of two hereditary (97/544, 97/545; lanes 2 and 3), two early onset (97/670, 96/10; lanes 
1 and 4) breast cancer cases, and control (lane 5) sample is shown in figure 33. A similar 
shift has been observed in samples 97/544 and 96/10 (lanes 2 and 4 respectively) which 
was later found to be present in two additional hereditary (97/137, 97/477), three 
additional familial (96/7, 97/474, 97/475) and eight additional early onset (96/5,97/270, 
97/344, 97/632, 97/681,97/683,97/684, 98/18) breast cancer case. This shift was further 
analyzed in each of these patients by DNA sequencing.
X X n .B R C A l  exon 11J
mnWi·.'·,·
Figure 33. Heteroduplex analysis of BRCAl exon IIJ.
Lanes 1, 97/670; 2, 97/544; 3, 97/545; 4, 96/10; 5, control. Arrow indicates the shifted 
fragment.
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BRCAl exon 1 IK is amplified with primers KF and KR as a fragment of 450 bp. Results 
of one familial (97/702; lane 1), three early onset (97/703, 98/17, 98/18; lane 2, 3, and 4 
respectively) breast cancer cases, and control (lane 5) sample is shown in figure 34. No 
shifts were observed in any one of the samples.
3.3.12. BRCAl exon IIK
Figure 34: Heteroduplex analysis of BRCAl exon IIK .
Lane 1, 97/702; Lane 2, 97/703; Lane 3, 98/17; Lane 4, 98/18; Lane 5, control.
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BRCAl exon 13 is amplified with primers 13F and 13R as a fragment of 259 bp. Results 
of one familial (98/60; lane 4), three early onset (97/703, 98/17, 98/18; lanes 1, 2, and 3 
respectively) breast cancer cases, and control (lane 5) sample is shown figure 35. No 
shifts were observed in any one of the samples.
3.3.13. BR CA l exon 13
Figure 35. Heteroduplex analysis of BRCAl exon 13.
Lanes 1, 97/703; 2, 98/17; 3, 98/18; 4, 98/60; 5, control.
105
BRCAl exon 20 is amplified with primers 20F and 20R as a fragment of 220 bp. Results 
two hereditary (96/1, 96/2; lanes 1 and 2 respectively), four familial (96/3, 96/4, 96/6, 
96/7; lanes 3, 4, 6, and 7 respectively), one early onset (96/5; lane 5) breast cancer cases, 
and control (lane 8) sample is shown in figure 36. No shifts were observed in any one of 
the samples.
3.3.14. BRCAl exon 20
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Figure 36. Heteroduplex analysis BRCAl exon 20.
Lanes 1, 96/1; 2, 96/2; 3, 96/3; 4, 96/4; 5, 96/5; 6, 96/6; 7, 96/7; 8; control.
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BRCAl exon 24 is amplified with primers 20F and 20R as a fragment of 275 bp. Results 
of three early onset (97/343, 97/344, 97/359; lanes 1, 2, and 3 respectively) breast cancer 
cancer cases, and control (lane 4) is shown in figure 37. No shifts were observed in any 
one of the samples.
3.3.15. BR CA l exon 24
Figure 37. Heteroduplex analysis of BRCAl exon 24.
Lanes 1, 97/343; 2, 97/344; 3, 97/359, 4, control.
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BRCA2 exon 1 la is amplified with primers aF and aR as a fragment of 1156 bp. Results 
of two hereditary (97/544, 97/545; lanes 2 and 3 respectively), one familial (96/8; lane 
1) breast cancer cases, and control (Lane 4) sample is shown in figure 38. Heteroduplex 
formation was observed in samples 97/544 and 97/545 (lane 2 and 3) who are a father 
and daughter pair both affected with breast cancer (Family 22).
3.3.16. BRCA2 exon İla
Figure 38. Heteroduplex analysis of BRCA2 exon 11a.
Lanes 1, 96/8; 2, 97/544; 3, 97/545; 4, control. Arrows indicate shifted fragments.
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BRCA2 exon 1 lb is amplified with primers bF and bR as a fragment of 1162 bp. Results 
of three hereditary (96/1, 97/544, 97/545; lanes 1, 3, and 4 respectively), one familial 
(96/8; lane 2), two early onset (97/631, 97/694; lanes 5 and 6 respectively) breast cancer 
cases, and control (lane 7) is shown in figure 39. Heteroduplex formation was observed 
in samples 97/544 and 97/545 (lanes 3 and 4 respectively) who are a father daughter 
pair (Family 22).
3.3.17.5/?C42 exon l ib
Figure 39. Heteroduplex analysis of BRCA2 exon 11b.
Lanes 1, 96/1; 2, 96/8; 3, 97/544; 4, 97/545; 5, 97/631; 6, 97/694; 7, control.
109
The overlapping region of BRCA2 exon 11a and b is amplified as a fragment of 274 bp 
(Figure 40), in order to localize the exact site of the mutation causing to shifted 
fragments in samples of the father (97/544) and his daughter (97/545).
3.3.18. BRCA2 exon lla-b
Figure 40. Heteroduplex analysis of BRCA2 exon lla-b.
Lanes 1,97/544; 2, 97/545; 3, control. Arrows indicate shifted fragments.
1 1 0
BRCA2 exon 1 Ic is amplified with primers cF and cR as a fragment of 1534 bp. Results 
of five male (97/694, 97/695, 98/3, 98/15, 98/59; lanes 1, 2, 3, 4, and 5 respectively) 
breast cancer cases, and control (lane 6) is shown in figure 41. No shifts were observed 
in any one of the samples.
3.3.19. BRCA2 exon 11c
1
Figure 41. Heteroduplex analysis of BRCA2 exon 11c
Lane 1, 97/694; 2, 97/695; 3, 98/3; 4, 98/15; 5, 98/59; 6, control.
I l l
BRCA2 exon 1 Id is amplified with primers dF and dR as a fragment of 931 bp. Results 
of six male (97/694, 97/695, 98/3, 98/12, 98/15, 98/59; lanes 1, 2, 3, 4, 5, and 6) breast 
cancer cases, and control (lane 7) sample is shown in figure 42. No shifts were observed 
in any one of the samples.
3.3.20. BRCA2 exon l id
1 2
Figure 42. Heteroduplex analysis of BRCA2 exon l id
Lanes 1, 97/694; 2, 97/695; 3, 98/3; 4, 98/12; 5, 98/15; 6, 98/59; 7, control.
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BRCA2 exon 1 le is amplified with primei eF and eR as a fragment of 782 bp. Results of 
four male (97/694, 97/695, 98/15, 98/59; lanes 1, 2, 3, and 4 respectively) breast cancer 
cases, and control (lane 6) sam.ple is shown in figure 43. No shifts were observed in any 
one of the samples.
3.3.21. BRCA2 exon İle
Figure 43. Heteroduplex analysis of BRCA2 exon l i e
Lanes 1, 97/694; 2, 97/695; 3, 98/3; 4, 98/15; 5, 98/59; 6, control.
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BRCA2 exon I l f  was amplified with fF and fR as a fragment of 1253 bp. Results of 
four male (97/631, 97/694, 97/695; lanes 1, 2, and 3 respectively) breast cancer cases, 
and control (lane 4) is shown in figure 44. No shifts were observed in any one of the 
samples.
3.3.21. J?/fC42 exon I lf
Figure 44. Heteroduplex analysis of BRCA2 exon I lf .
Lanes 1, 97/631; 2, 97/694; 3, 97/695; 4, control.
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BRCA2 exon l lg  was amplified with primers gF and gR as a fragment of 899 bp. 
Results of three hereditary (96/2, 97/544, 97/545; lanes 1, 2, and 3 respectively) breast 
cancer cases, and control (lane 4) sample is shown in figure 45. Heteroduplex formation 
has been observed in patient 96/2 (lane 1).
3.3.22. BRCA2 exon l lg
Iff
Figure 45. Heteroduplex analysis o\B R C A 2  exon llg .
Lanes 1, 96/2; 2, 97/544; 3, 97/545; 4: control. Arrow indicates the shifted fragment.
115
BRCA2 exon llg-26 was amplified with 26F and 26R as a fragment of 290 bp (Figure 
46), in order to localize the exact site of the mutation causing the shifted fragment in 
patient 96/2.
3.3.23. BRCA2 exon llg-26
Figure 46. Heteroduplex analysis of BRCA2 exon llg-26.
Lanes 1, 96/2; 2, control. Arrow indicate the shifted fragment.
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Approximately 40% of BRCAl and BRCA2 mutations are frameshift type. DNA 
sequencing of PCR products bearing frameshift mutations are difficult to analyze 
because of the presence of two different framed alleles. In order to facilitate the 
sequence analysis and to be able to clearly identify these kind of mutations most of the 
patients’ shifted fragment were reamplified and cloned into pGEM TEAsy vector. DNA 
sequencing of several clones permit to identify the wild type and mutant alleles 
separately.
3.4. Cloning
3.4.1. Mini prep DNA Isolation
Plasmid DNA samples were isolated from white colonies which are expected to have the 
inserted fragment. Mini prep DNA isolation was done by alkaline lysis procedure 
followed by phenol chloroform extraction. All extracted DNA samples were evaluated 
quantitatively and qualitatively by spectrophotometry and agarose gel electrophoresis. 
The concentrations of the mini prep DNA samples on figure 47 were 100 ng/|il, 150 
ng/'p.!, 250 ng/pl, 215 ng/|il, 200 ng/ml, 155 ng/|j.l, 185 ng/|Ltl respectively.
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Figure 47. Agarose gel electrophoresis of extracted mini prep DNA samples of 
97/641 BRCAl exon IIB .
Lanes 1, clone 1; 2, clone 2; 3, clone 3; 4, clone 4; 5, clone 5; 6, clone 6; 7, clone 7.
3.4.2. Restriction Endonuclease Analysis
In order to select plasmids containing the insert, mini prep DNA samples of white 
colonies were further digested with EcoRI restriction endonuclease from each site of the 
insert. Presence of the insert with an expected size fragment was confirmed by agarose 
gel electrophoresis of digested products (Figure 48).
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Figure 48. Restriction endonuclease analysis of 9H64X mini prep DNA samples.
Lanes 1, clonel; 2, clone 2; 3, done 3; 4, clone 4; 5, clone 5; 6, ^XMAIHinfi molecular 
weight marker. Arrow indicate the excised insert from pGEM TEasy vector.
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3.4.1. Hereditary Breast and/or Ovarian Cancer
In this group of six patients selected on the basis of having at least two affected first 
degree relatives and those with bilateral breast cancer plus one affected first degree 
relative were studied. Two BRCA2 alterations were found in two families.
Heteroduplex analysis of family 22 revealed shifts in both BRCA2 exon 11 a and b. 
Further analysis localized this shift to the overlapping 274 bp region of these two 
fragments in the father (97/544) and daughter (97/545). Sequencing analysis of PCR 
products revealed very ambigous results indicating an insertion or deletion type mutation 
(Data not shown). Thus, in order to determine the exact mutation, PCR products of 
97/544 and 97/545 were cloned into pGEM Teasy vector. .Several clones were 
sequenced with both forward and reverse primers. DNA sequencing results showed a 
four base pair deletion (AAAC) starting at nucleotide 3034, which leads to protein 
truncation at codon 958 (Figure 49). This mutation which was previously reported by 
Phelan and co-workers (Phelan ei al, 1996) had occurred in a repeat region frequently 
involved in DNA polymerase slippage errors causing frameshifts.
Heteroduplex analysis of 96/2 showed a shifted fragment in BRCA2 exon 1 Ig. Further 
analysis revealed that this shift was the result of an alteration that was present in the last 
three portion of this fragment. Sequencing analysis revealed that there was a G insertion
3.4. DNA Sequence Analysis
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at nucleotide 6880 resulting in a premature protein product that was terminated at codon 
2224 (Figure 50).
Figure 49. Deletion AAAC in BRCA2 exon 11.
a: Control sample: DNA sequence obtained with forward primer, b: control sample: 
DNA sequence obtained with reverse primer, c: clone sample of 97/544: DNA 
sequence obtained with forward primer, d: clone sample of 97/544: DNA sequence 
obtained with reverse primer. Arrows indicate the four bp deletion at nucleotide 3034.
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aFigure 50. Insertion G in BRCA2 exon 11.
a. Control sample: DNA sequence obtained with forward primer, b. control sample: 
DNA sequence obtained with reverse primer, c. clone sample of 96/2: DNA sequence 
obtained with forward primer, d. clone sample of 96/2: DNA sequence obtained with 
reverse primer. Arrows indicate the G insertion at nucleotide 6880.
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In addition, patients 97/137, 91lA'll, and 97/544 who belong to hereditary group 
showed a similar shift in BRCAl exon IIJ. DNA sequencing revealed an A—>G 
transition at nucleotide 3667, resulting in a substitution of lysine for arginine (Figure 
51). This missense mutation was previously reported as a frequent polymorphism. In our 
hereditary group, this polymorphism v/as found in three out of five cases (60%).
3.4.2. Familial Breast Cancer
Patients who only have one affected first degree relative also diagnosed with breast 
cancer were classified as the familial group. No frameshift or nonsense BRCAl or 
BRCA2 mutation was observed. One patient (96/8) from familial group had an alteration 
in BRCAl exoiil lb. DNA sequence analysis revealed a novel silent mutation at codon 
298 (Figure 52). In addition, two previously reported BRCAl polymorphisms 3667 
A-^G in patients 96/7, 97/474, 97/475 (37%) and 2731 C-^T (P871L) in patients 
97/702,98/60 (25%) (Figure 53) were observed.
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Figure 51. K1183R polymorphism in BRCAl exon 11.
a. Control sample: DNA sequence obtained with forward primer, b. control sample: 
DNA sequence obtained with reverse primer, c. sample 96/10: DNA sequence obtained 
with forward primer, d. sample 96/10: DNA sequence obtained with reverse primer. 
Arrows indicate A—>G transition at nucleotide 3667.
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Figure 52. N298N silent mutation in BRCAl exon 11.
a. Control sample: DNA sequence obtained with forward primer, b. control sample. 
DNA sequence obtained with reverse primer, c. sample 96/8: DNA sequence obtained 
with forward primer, d. sample 96/8: DNA sequence obtained with reverse primer. 
Arrows indicate T— transition at nucleotide 1013.
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Figure 53. P871L polymorphism in BRCAl exonll.
a. control sample; DNA sequence obtained with forward primer, b. control sample: 
DNA sequence obtained with reverse primer. Arrows indicate C ^ T  transition at 
nucleotide 2731, c. sample 97/359: DNA sequence obtained with forward primer, d. 
sample 97/359: DNA sequence obtained with reverse primer.
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Women diagnosed as having breast cancer before age 35 years, none of whom were 
selected on the basis of family history status were in the early onset group. A novel 
BRCAl frameshift mutation, 1200 insA was identified in patient 97/641 (Figure 54). 
One patient, 97/670, has showed an alteration in BRCAl exon HE. DNA sequence 
analysis of PCR products revealed one silent and two heterozygous missense mutation. 
One of the missense mutations, 2196 G-^A (Figure 56) resulting in the substitution of 
aspartic acid for asparagine at codon 693 was a previously reported polymorphism, as 
the silent mutation at codon 694 (2201 C-»T). However, the missense mutation from A 
to G at nucleotide 2080 (K654E), was novel (Figure 55). In order to determine the phase 
of these transitions patient’s PCR product was cloned into pGEM Teasy vector. DNA 
sequencing of multiple clones revealed that transitions 2196 G->A and 2201 C-^T are 
on the same allele and transition 2080 A—>G is on the other allele.
In addition BRCAl 111 shifts detected in nine patients (33%) from early onset group 
(96/5, 96/10, 97/270, 97/344, 97/359, 97/632, 97/684, 98/17, 98/18), has been shown to 
be the result of 3667 A to G polymorphism. One patient in this group (97/682) was 
found to have a novel silent mutation (1013 T->C). Another patient (97/508) who 
showed an altered fragment in BRCAl exon IIG, was shown to carry the 2731 C—>T 
polymorphism.
3.4.3. Early Onset Breast Cancer
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aFigure 54. Insertion A in BRCAl exon 11.
a. Control sample: DNA sequence obtained with forward primer, b control sample; 
DNA sequence obtained with reverse primer., c sample 97/641: DNA sequence obtained 
with forward primer, d. sample 97/641; DNA sequence obtained with reverse primer. 
Arrows indicate the A insertion at nucleotide 1200.
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Figure 55. K654E missense mutation in BRCAl exonll.
a. Control sample; DNA sequence obtained with forward primer, b. control sample: 
DNA sequence obtained with reverse primer, c. clone sample 97/670; DNA sequence 
obtained with forward primer, d. clone sample 97/670; DNA sequence obtained with 
reverse nrimer Arrows indicate A—> G transition at nucleotide 2080
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Figure 56. D693N polymorphism and S694S silent mutations in BRCAl exoiill.
a. Control sample: DNA sequence obtained with forward primer, b. control sample. 
DNA sequence obtained with reverse primer, c. sample 97/670; DNA sequence 
obtained with forward primer, d. sample 97/670; DNA sequence obtained with reverse 
primer. Arrows indicate G ^ A  and C ^ T  transitions at nucleotides 2196 and 2201
respectively.
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The fourth group we studied was composed of isolated male breast cancer cases. We 
were unable to detect any BRCAl or BRCA2 mutations in this group.
3.4.4. Male Breast Cancer
134
4. DISCUSSION
Breast cancer is one of the most common malignancies affecting women. Inherited gene 
mutations may be responsible for 5-10% of breast cancer cases (Miki et al, 1994; 
Thorlacius el al., 1998; Feunteun el al., 1999). In Turkish women, breast cancer is 
among the most common malignancies (Karaoguz and içli, 1993). The frequency and 
the types of germ-line mutations leading to breast/ovarian cancers in the Turkish 
population is not well known. In this study, germ-line and/or mutations
were screened in 50 breast and/or ovarian cancer patients. We employed a BRCAl and 
BRCA2 mutation screening strategy which is based on the analysis of exons that have 
been reported to harbor majority of the previously reported mutations in these genes. 
Selected regions of BRCAl (exons 2, 5, 11, 13, 20 & 24), and BRCA2 (exon 11) were 
subjected to heteroduplex analysis, and altered fragments were further analyzed by DNA 
sequencing. According to the Breast Information Core database, these BRCAl and 
BRCA2 regions harbor 80% and 45% of the mutations respectively. Nine different 
sequence alterations (seven for BRCAl and two for BRCA2) were identified in 25 
patients. In BRCA2, one previously reported deletion (3034 delAAAC), and one novel 
insertion (6880 insG) -  type of frameshift mutations leading to protein truncation were 
observed. In BRCAl, one novel frameshift mutation (1200 insA), one novel unclassified 
variant (2080 A—>G; K654E), and one novel silent mutation (1013 T ^ C ; N298N) were
135
identified. In addition, four previously reported BRCAl polymorphisms (three missense 
and one silent mutations) were also found in these Turkish breast cancer patients (see 
Table 1) (Ozdag etal., in press).
The patients were divided into four groups of hereditary (n=6) breast/ovarian cancer, and 
familial (n=7), early onset (n=27) or male (n=10) breast cancer. Both BRCAl and 
BRCAl genes were analyzed in all the groups.
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4.L Mutation Screening
Mutation screening of BRCAl and BRCA2 genes are rather difficult because of their size and the 
wide variety of mutations all along the exons. ITiere are several indirect screening methods used 
frequently by different groups, such as HA, SSCP, PTT and DHPLC. Among them DHPLC is the 
most sensitive indirect screening method. Its sensitivity is almost 100%, however it needs special 
and expensive equipment. PTT is one of the most suitable technique for BRCAl and BRCAl 
genes due to a large number of protein truncating type of mutations. It is 100% sensitive in 
truncating mutation detection and allows to screen kilobase long fragments. The sensitivity of 
HA and SSCP is nearly 100% in detecting deletion-insertion type of mutations. However their 
sensitivity is approximately 70% in detecting point mutations. SSCP allows to screen fragments 
up to 300bp. Its sensitivity decreases fragments over 300bp long.
Since it is an inexpensive, rapid method and turned out to be sensitive enough for screening long 
fragments, HA has been used as the main indirect screening method in this study. Although its 
sensitivity in detecting point mutations is 70%, this technique allowed us to screen fragments 
upto 1250bp. We could detect deletion-insertion type mutations in fragments over one kb. Since 
40% of reported mutations are deletion-insertion type mutation, HA which does not need any 
special equipment or expensive kits, was found to be rather efficient. In addition, with this 
technique it is possible to analyze up to 200 samples on a 45X38 sequencing grade 
polyacrylamide gel electrophoresis apparatus by loading the samples sequentially.
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Following this screening, identification of mutations was done by automated DNA sequencing. 
We would like to note that it is rather difficult to identify frameshift mutations are hardly 
identified by automated DNA sequencing since the results are based on the sequencing of both 
alleles of an individual. Although it is possible to define the first nucleotide affected by the 
mutation, a very ambigous peak pattern dominates the results. In order to overcome this 
difficulty, we cloned and sequenced the alleles separately.
4.2.Hereditary Breast Cancer
In the hereditary group which consists of probands with at least two affected first degree 
relatives, and those with bilateral breast cancer plus one affected first degree relative (Table 2), 
we identified two BRCA2 frameshift mutations, 6880 insG (Figure 46 & 50) and 3034 delAAAC 
(Figure 40 & 49), in two of the six families (33%). Interestingly no BRCAl mutation was found 
in anyone of the patients except for a previously reported frequent polymorphism which is an A 
to G transition at nucleotide 3667 in three (50%) (Figure 33 & 51) families.
139
IM
α
0о
и
М )
и
осСЛ
U
и
>
0
1
Ч-*
м
PÛ
- в
б
б
'i·*
Gf)
б
и
PÛ
'S
g
б
1^
і
б
'S
ä
η
JSGA
6
H
c^
-d
C
* d
c
Э
QA
C
O
6
s
'dc
d
GA
eu
Oc
O)
x :Ph
•00
3
d
H
CA
0>
<υ
U
CA
t ^ÿ S
c
O O
U
O
Uc
d
U
o>
d>
UODCJ
d  ^
* 5  ^d  m
O  S
«a L· 
·*·* ^  Й T>
0·) Ό
¿  ^
• |  «
S
* d
іЗ
"чPi
O
&  " o
■e
0>
T) ç-> 
рц <i>
C
.2*z»d
d
s
> >
1d
pH
a
d
O
Ü
·г^
a>
>
(N
Й
O
» 0
m
O?
40
T3d
3
oo
d-
Д m ‘гГ
ДЗ cd --N 40 enO Oùd t_t Ö aS c^ · (D jO
2 > 3 3
en Ц0P ' J O  . . U
CN
»/')
‘Г)‘ri
bi*oo ‘П O oTV oí ‘/Ί CN^ en c i o\ ‘П r-H ‘n en OΌ in O^ 40 40 »n rf en <N en un 40 unw ·^—^ ^
1-H Osl r-H r—^ en OvJ 1-H r ·^
T3
s »n
*‘П *OÍ l>
**en 40 CN| O r-H 00 40dPÛ Ov| en en ‘П un ‘П ‘П en en en en
CN(Nrs|
t00
O
g
00VO
c>î
<O
Pi
m
00‘Oσ^eu
2СЛ
P-H ^
b  ^Q
OCN CN(N
s:
λ,
O
a
O  ‘O
O
en ^  40
g  ^Ş O
Os 00 40
O
(D
L·<L)'Й
I
(UЙO
nd
a aïï 3
g.ob
Cd
cd 2  ^^  Í? ’S
^ Й-З
d) O  ID
Ö
(D 'Й  ^
g S fe.2 - O
'g S S 
8 '-a 
ϊΉ  2
§
cd D  >   ^ Си'ТЗ ^
■ S e le w s
| 1 1
S ^ .Ë
дЗ O "ЙH > S
Ö -   ^I  8 S 
s  Jü feb0 w D
Д  cd
•g S ?
 ^ Ş c
1   ^ S2 -§
S ^  ÿ
PQ O §
î  1 1to 2
§ '§  O
1 S I
-  Щ-т
8 P sJ> feb'l
2  i l
(D cd
PQ Д  T3* -  c;
One of tlie BRCA2 mutations identified in this group is not reported previously. This 
novel insertion type mutation was found in patient 96/2 (Figure 18). The insertion of G 
at nucleotide 6880 causes a protein truncation signal at codon 2224. The other BRCA2 
mutation, the deletion of AAAC at nucleotide 3034, was identified in patients 97/545 
(44 years old) and her father 97/545 (74 years old) (Figure 18). This frameshift 
mutation, which occurred in an A repeat region, was probably the result of a DNA 
polymerase slippage error frequently involved in such alterations. This four base pair 
deletion was first reported by Phelan et al.
4.3. Familial Breast Cancer
Patients who have one affected first degree relative also diagnosed with breast cancer 
constitute the familial group. No frameshift or nonsense BRCAl or BRCA2 mutations 
was observed. However, previously reported BRCAl polymorphisms 3667 A—>G was 
present in three (42%) and 2731 C—>T was present in two (28%) (Figure 30 & 53) 
patients. In addition, a novel silent BRCAl mutation (1013 T-^C) (Figure 52) was 
identified in one patient.
4.4. Early Onset Breast Cancer
Women diagnosed as having breast cancer before age 35 years, none of whom were 
selected on the basis of family history status, were in the early onset group. A novel 
BRCAl frameshift mutation, 1200 ins A (Figure 25 & 54), was identified in one patient.
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In addition, five different BRCAl sequence alterations were observed in 12 patients. 
These alterations include one novel (1013 T—>C), and four previously reported 
polymorphisms (see Table 1). The 3667 A ^ G  polymorphism was observed in 33% 
(9/27) of the patients. Interestingly each allele of BRCAl displayed a missense mutation 
in one patient; a previously described rare polymorphism (2196 G->A; D693N) (Figure 
28 & 56) and a novel missense mutation (2080 A—>G; K654E) (Figure 55). This patient 
also carried a silent mutation (2201 C—>T) co-segregating with the 2196 G—>A mutation. 
The phase of these transitions was determined by cloning of patient’s PCR product and 
sequencing of multiple clones. These experiments established that sequence alterations 
2080 A—>G and 2196 G—>A which lead to amino acid substitutions K654E and D693N 
respectively were independently inherited. Sequence analysis showed that 2080 A ^ G  
mutation v'as absent in one hundred independent alleles from a control population. The 
novel K654E substitution is not in a conserved residue but when BRCAl sequence is 
subjected to secondary structure prediction programs SOPMA and GOR4^ this region 
forms a short alpha helix, carrying four consecutive lysine residues. Even though Lys to 
Glu substitution may increase the helix stability, it neutralizes positive charges on the 
helix which may have an important role for the structure and function of the protein. 
Occurrence of two mutant alleles in the same patient with a sporadic early onset 
malignancy (age 26) suggests that these mutations may be involved in the development 
of breast cancer.
(http://pbil.ibcp.fr/cgi-bin/secpred)
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Missense mutations which constitutes 27% of all BRCAl mutations are difficult to 
evaluate for their predicted effect. It is reported that although missense changes with 
unknown significance were seen in breast cancer cases and controls, no frameshift or 
nonsense mutations were observed in a group of control women with a first-degree 
family history (Malone et al, 1998). An amino acid change is considered as a missense 
mutation when is not present in the normai population (Roth et al, 1998). But even these 
criteria are not adequate to clarify the possible effect of a missense mutation.
SOPMA
Wild type sequence C S S S E E I K K K Y N Q M P V R H S
2"'* structure c c c h h h h h h h h h c c c c c c  c
Wild type sequence C S S S E E I K E K Y N Q M P V R H S  
2”'* structure c c c h h h h h h h h h c  c c c c c c
GOR4
Wild type sequence C S S S E E I K K K Y N Q M P V R H S
2"'· structure c c c h h h h h li h h h c c c c c c c
Wild type sequence C S S S E E I K E  K Y N Q M P V R H S
2"** structure c c c h h h h h h h h h c c  c c c c c
Figure 57. Secondary structure prediction of K654E substitution.
There are several controversial reports on this issue. A missense mutation, Serl040Asn, 
reported as a polymorphism by Castilla et al, because it was found not to segregate with 
the disease and was also detected in three of 232 control chromosomes (Castilla et al, 
1994). However this alteration did segregate with the disease in the family in which it
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was identified and was absent in 120 control chromosomes (Friedman et al, 1994). 
Another example was provided by a collaborative survey from Shattuck-Eidens et al, 
reporting an amino acid change, Argl347Gly, as a missense mutation in a Utah family 
an stating that it was absent in 156 control chromosomes. However, this same variant 
was found in a patient studied by the Berkeley group who also had a severe frameshift 
mutation implying that its functional significance is questionable (Shattuck-Eidens et al, 
1995).
4.5. Male Breast Cancer
The fourth group we studied was composed of isolated male breast cancer cases. We 
were unable to detect BRCAl or BRCA2 mutations in this group. In a previous study, 
BRCA2 mutations were found in 2% of non-familial male breast cancer cases (Friedman 
et al, 1997). Thus BRCA2 appears not to contribute significantly to isolated male breast 
cancer.
4.6. Conclusion and Perspectives
A wide variation in BRCAl and BRCA2 mutation spectrum and frequency has been 
reported for different populations (Szabo and King, 1997). In our Turkish patients with 
hereditary breast cancer, BRCA2 mutations accounted for 33% of the families. This 
frequency is rather high similar to the Icelandic population. Interestingly, BRCAl 
mutations in our study group appear to be rare - if not exceptional similar to patients
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from Iceland, Norway, and Japan. However, in a recently published paper, Balo et al. 
reported BRCAl mutations in two out of five hereditary breast cancer cases as compared 
to one BRCAl mutation (Balo et al, 1999). We did not detect BRCAl or BRCAl 
mutations in familial breast cancer cases. Malone et al reported that 18% of women 
diagnosed as having breast cancer before age 35 years, none of whom were selected on 
the basis of family history status, had germline BRCAl mutations. Whereas they found 
that 7% of women diagnosed before age 45 years and had a first-degree relative with 
breast cancer had germline mutations in BRCAl (Malone et al, 1998). These results 
confirmed the report of Couch et al who found a BRCAl mutation in 7% of women with 
a family history of breast cancer or who had early-onset breast cancer themselves. The 
said group of women was broader than the studies that focus on large families 
containing many members with breast cancer, ovarian cancer or both. Thus these results 
indicate that mutation frequency decreased with increasing age of diagnosis and higher 
proportions of mutations were seen in cases with at least one relative diagnosed as 
having breast cancer before age 45, in cases with greater numbers of affected relatives, 
and those with ovarian cancer family history (Couch et al, 1997). To the best of our 
knowledge, BRCAl mutations in this group have not been reported previously. Although 
we did not screen all exons of BRCAl our observations suggest that BRCAl gene also is 
infrequently involved in familial breast cancer. The results obtained from this study 
indicate that BRCAl and BRCAl genes are involved in the development of some but not 
all hereditary breast cancers in the Turkish population as reported for other population 
(Sobol etal., 1994; Serova etal., 1997).
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The extent of family history is very important in evaluating the role of BRCAl and 
BRCA2 genes in breast cancer. In families with six or more breast cancer cases, in the 
presence of both male and female patients, BRCAl and BRCAl mutations account for 
90% of all cases. Whereas in the presence of only male patients this ratio is 80% (20% 
BRCAl and 60% BRCAl). In the presence of breast and ovarian cancer cases in these 
families BRCAl mutations account for 80% and BRCAl mutations account for 15% of 
all cases. However, in families with four or less breast cancer cases BRCAl mutations 
account for 30% and BRCAl mutations account only for 5% of all cases (Easton, 1997).
In our hereditary and familial groups four or less breast cancer cases were documented 
among the family members. Although BRCAl mutations seem to be high, the mutation 
ratio found in our study groups (Table 9) is compatible with the previous reports 
discussed above.
Table 9. BRCAl and BRCAl mutation frequencies in different patient groups.
PATIENT GROUPS BRCAl BRCAl
Hereditary breast and/or ovarian cancer (n=8) 0 (0%) 2 (33%)
Familial breast and/or ovarian cancer (n=6) 0 (0%) 0 (0%)
Early onset breast cancer (n=27) 1 (4%) 0 (0%)
Male breast cancer (n=10) 0 (0%) 0 (0%)
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In this study we have screened only the selected regions of both genes covering most of 
the mutations reported to date. Although the results obtained from this research seems to 
reflect the actual situation, mutation screening of remaining exons of both genes may 
give a more complete picture about the role of BRCAl and BRCA2 genes in this group of 
patients. Recent data suggest that BRCA2 exons other than exon 11 harbor an important 
number of mutations in males without a family history (Csokay B. et al, 1999). Thus 
screening of the remaining exons of BRCA2 will have an important value especially for 
the male breast cancer group.
Rearrangement type of mutations which can not be identified by PCR based methods, 
explain an important part of hereditary breast cancer cases. These kinds of aberrations 
have been reported several times for BRCAl (Swensen et al, 1997; Puget et al, 1997; 
Puget et al, 1999a; Puget et al, 1999b; Mazoyer and BRCAl exon 13 Dup. Scr. Gr.,
2000). Thus in order to fully analyze BRCAl and BRCA2 genes, rearrangement should 
also be screened.
Besides the arguments about the presence of other putative breast cancer susceptibility 
genes, the effect of endogenous and exogenous hormones, environmental factors, and 
genetic polymorphisms in metabolizing enzymes are also very important contributors in 
completing the picture of breast carcinogenesis. It is thus possible to conclude that 
cancer is both a multistep and a “multifactorial” disease.
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ABSTRACT
Germ-line B R C A l  and/or B R C A 2  mutations were screened in 50 Turkish 
breast and/or ovarian cancer patients composed of hereditary, familial, 
early onset, and male cancer groups. Genomic DNA samples were tested by 
heteroduplex analysis and DNA sequencing. Two truncating B R C A 2  
mutations, one novel (6880insG) and one previously reported 
(3034delAAAC), were found in two out of six (33%) hereditary breast 
and/or ovarian cancer patients. A novel truncating (1200insA) and a
missense (2080A^G) B R C A l  m.utation was found in two of 27 (8%) 
individuals in the early onset group. A total of four (8%) disease causing 
mutations in 50 breast cancer patients were identified in B R C A l  and 
B R C A 2  genes. In addition, five B R C A l  sequence variants have been 
identified in 23 patients. These results indicate that B R C A l  and B R C A 2  
genes are involved in some but not all forms of hereditary predisposition 
to breast cancer in the Turkish population.
Key words: Hereditary breast/ovarian cancer; BRCAl· ,  BRCA2;  germ-line 
m utation
INTRODUCTION
Breast cancer is one of the most common malignancies affecting women^ 
Inherited gene mutations may be responsible for 5-10% of breast cancer 
cases (1, 2,3). Ovarian cancer is also known to have a familial component 
(4).
Two genes associated with inherited predisposition to breast and/or 
ovarian cancer have been identified. These are B R C A l  on chromosome 
17ql2-21 (1), and B R C A 2  on chromosome 13ql2-13 (5). Population genetics 
studies aiming to determine the relative contributions of these genes in  
hereditary breast and/or ovarian cancer have shown a wide variation 
among different populations (6). For example, in families with three or 
more cases of female breast and/or ovarian cancer, B R C A l  mutations are 
as low as 9% in Iceland and as high as 79% in Russia. A similar variation 
has been documented for BRC A 2  mutations as well, which can be 
examplified by 8% in Finland and 64% in Iceland. In affected women 
before age 45 years with a first-degree relative, B R C A l  mutations account 
for 7% of the families (7). In families with both male and female breast 
cancer, B R C A 2  mutations were documented in 19% of North American, 
33% of Flungarian, and 90% of Icelandic populations (6). In isolated male 
breast cancer cases, a very low frequency of B R C A 2  mutations has been 
reported (8). In early onset breast and/or ovarian cancer patients not
htiD://www.nci.nih.eov/Dublic/fiactbook98/incidence.htni
selected for family history, 4-9% have B R C A l, and 2-8% have BRCA2 
m utations (6, 7).
Breast cancer is among the most common malignancies in T urk ish  
wom en (9). The frequency and the types of germ-line m utations invo lved  
in Turkish breast/ovarian  cancers are not well known. In order to 
determ ine the contributions of BRCAl and BRC Al m utations to the 
developm ent of breast an d /o r ovarian cancer in the Turkish population, 
we screened pre-selected regions of these genes in four groups of patients 
composed of hereditary and familial cancer, as well as early onset and m ale 
breast cancer.
PATIENTS AND METHODS
Families
We analyzed a total of 50 genomic DNA samples isolated from white blood 
cells of breast cancer patients. The samples were collected from the Medical 
Schools of Hacettepe, Istanbul, Ankara Universities, and Ankara Oncology 
Hospital. Informed consent was obtained from all participants. Each 
proband was interviewed for pedigree construction including in form ation  
concerning the family history of breast, ovarian, and other cancers. Based 
on pedigree analysis, patients were divided into four groups. Available 
medical and pathological records were reviewed to verify the diagnoses. 
The phenotypical characteristics of the families included in the study are 
sum m arized in Table 1.
PCR and heteroduplex analysis
DNA isolation was perform ed from 1 ml peripheral blood by 
phenol/chloroform  extraction (10). Exons 2, 5, 11 (10 overlapping 
fragments), 13, 20, 24 of B RC A l, and exon 11 (7 overlapping fragments) of 
BRCA2 were screened for m utations by heteroduplex analysis using 
previously reported primers (11, 12). PCR was performed in a total vo lu m e
of 10 |il, w ith lOX buffer, 1.5 U Taq polymerase, 1.5 mM MgCl2, 200 }iM 
dNTP, 10 pmol of each primer, and IpCi of [32p] dCTP (specific activity 3000 
Ci/m m ol). PCR conditions were as follows, 940C for 3 min, 30 cycles of 30 
sec at 94®C, 30 sec at 550C, and 30 sec at 72®C. 10 m in of 72®C was added as
the extension step. PCR products were denatured at 950C for 10 min, and 
left at 3 70c  for 2 hours. 5 pi of PCR products were loaded on to 6% native  
polyacrylamide gels, and run  at 400V for 16 hours. The gels were th en  
dried and exposed to X ray films O /N  at -80°C.
Sequencing
Fragments that showed an alteration in heteroduplex analysis were 
ream plified for sequencing. The prim er pairs for BRCAl did not change. 
However, B RC Al exon 11 was subdivided into 26 overlapping fragm ents 
for DNA sequencing reactions (12). PCR was perform ed in a total v o lu m e
of 50 pi, w ith lOX buffer, 1.5 U Taq polymerase, 1.5 mM MgClj, 200 pM
dNTP, and 10 pmol of each primer. PCR conditions were as follows, 94°C 
for 3 min, 30 cycles of 30 sec at 94^C, 30 sec at 55°C, and 30 sec at 72®C. 10 
min of 72®C was added as the extension step. PCR products were sequenced 
using Am ersham  Therm osequenase Dye Term inator cycle sequencing kit, 
according to the m anufacturer's instructions, and analyzed on an ABI 377 
autom ated DNA sequencer or ABI 310 Genetic Analyzer.
M utations identified by direct sequencing were subjected to confirm atory 
analysis. For this purpose, PCR products were cloned into Promega pGEM 
TEasy TA cloning kit, according to the m anufacturer's directions. Several 
mini prep plasm id DNA samples for each patient were isolated by phenol 
chloroform  extraction and sequenced using Perkin Elmer Big Dye cycle 
sequencing kit.
RESULTS
Germ-line BRCAl an d /o r BRCA2 m utations were screened in 50 breast 
an d /o r ovarian cancer patients from Turkey. We employed a BRCAl and 
B RC A l m utation screening strategy which is based on the localization of 
previously reported m utations in these genes. Selected regions of BRCAl 
(exons 2, 5, 11, 13, 20 & 24), and BRC Al (exon 11) were subjected to 
heteroduplex analysis, and altered fragments were further analyzed by 
DNA sequencing. According to the BIC database^, these BRCAl and 
BRCAl regions harbor 80% and 45% of the mutations respectively.
The patients were divided into four groups of hereditary (n=6) 
b reast/ovarian  cancer, and familial (n=7), early onset (n=27) or male (n=10) 
breast cancer. The selected regions of both BRCAl and BRCAl genes were 
analyzed in all four groups.
Nine different sequence alterations (seven for BRCAl and two for BRCAl) 
were identified in 25 patients. In BRCAl, one previously reported deletion 
(3034 delAAAC), and one novel insertion (6880 insG) (Figure lA) -  type of 
fram eshift m utations leading to protein truncation were observed. In  
B RC A l, one novel frameshift m utation (1200 insA) (Figure IB), one novel
missense m utations (2080 A-»G; K654E) (Figure 2A), and one novel silent 
m utation (1013 T ^ C ; N298N) were identified. In addition, four previously
■ (http://vvww.nhgri.nih.gov/Intramural_research/Lab transfer/Bic/index.html
reported BRCAl polym orphism s (one silent and three m issense 
m utations) v/ere also found in these Turkish breast cancer patients (see 
Table 2).
Hereditary group consisted of patients w ith at least two affected first degree 
relatives, and those with bilateral breast cancer plus one affected first 
degree relative (Table 1). We identified two BRC Al frameshift m utations, 
6880 insG (Figure lA) and 3034 delAAAC, in two of the six families (33%) 
in this group. Interestingly no BRCAl m utation was found except for a 
previously reported frequent polym orphism  which is an A to G transition  
at nucleotide 3667 in three (50%) families.
Patients who have one affected first degree relative also -diagnosed w ith  
breast cancer constitute the familial group. No frameshift or nonsense 
BRCAl or BRC Al m utation was observed. However, previously reported 
BRCAl polym orphism s 3667 A-»G in three (42%), and 2731 C-»T in two 
(28%) patients were present. In addition, a novel silent BRCAl m u ta tio n  
(1013 T ^ C ) was identified in one patient.
W om en diagnosed as having breast cancer before age 35 years, none of 
whom  were selected on the basis of family history status were in the early 
onset group. A novel BRCAl frameshift m utation, 1200 ins A (Figure IB), 
was identified in one patient. In addition, five different BRCAl sequence 
alterations were observed in 12 patients. These alterations include one
novel (1013 T->C), and four previously reported polymorphisms (see Table 
2). The 3667 A-^G polym orphism  was observed in 33% (9/27) of the
patients. Interestingly each allele of BRCAl displayed a missense m u ta tion  
in one patient (Figure 2A and B): a previously described rare 
polym orphism  (2196 G ^ A ; D693N) and a novel missense m utation (2080
A->G; K654E). This patient also carried a silent m utation (2201 C-»T) co­
segregating w ith the 2196 G->A m utation. The phase of these transitions 
was determ ined by cloning of patient's PCR product and sequencing of 
m ultiple clones. This finding establishes that sequence alterations 2080
A-»G and 2196 G->A, which lead to amino acid substitutions K654E and 
D693N respectively, were independently inherited. Sequence analysis 
showed that 2080A ^G  m utation was absent in  one hundred  independent
alleles from a control population. The novel K654E substitution is not in a 
conserved residue but w hen BRCAl sequence is subjected to secondary 
structure prediction program s SOPMA and GOR4^ this region forms a 
short alpha helix, carrying four consecutive lysine residues. Even though  
Lys to Glu substitution may increase the helix stability, it neutralizes 
positive charges on the helix, which may have an im portant role for the 
structure and function of the protein. Occurrence of two m utant alleles in  
the same patient w ith a sporadic early onset malignancy (age 27) suggests 
that these mutations may be involved in the development of breast cancer.
fhttD://Dbil.ibcD.iT/cei-bin/secDred')
The fourth group we studied was composed of isolated male breast cancer 
cases. We were unable to detect mutations in the selected regions of 
B R C A l  and BRCA2  genes in this group.
In conclusion, among 50 Turkish breast cancer cases, we detected two (4%) 
B R C A 2  and one (2%) B R C A l  disease-causing frameshift mutations. In 
addition, one (2%) missense B R C A l  mutation, and five B R C A l  
polymorphisms in 23 patients (46%) was identified.
DISCUSSION
A wide variation in BRCAl and BRCA2 mutation spectrum and frequency 
has been reported for different populations (6). The results of our Turkish 
data is summarized in Table 3. In the hereditary breast cancer group, 
BRCAl mutations accounted for 33% of the cases. This frequency is rather 
high similar to the Icelandic population. Interestingly, BRCAl mutations 
in our study group appear to be rare - if not exceptional similar to patients 
from Iceland, Norway, and Japan. However, in a recently published paper. 
Balcı et al. reported BRCAl mutations in two out of five hereditary breast 
cancer cases as compared to one BRC Al mutation (13). We did not detect 
BRCAl or BRC Al mutations in familial breast cancer cases. Our BRCAl 
data confirm the observations of Malone et al. who identified BRCAl 
mutations in only 7% of the cases (7). To the best of our knowledge, 
BRC Al mutations in this group have not been reported previously. 
Although we did not screen all exons of B RC Al our observations suggest 
that BRC Al gene is also infrequently involved in familial breast cancer. 
The results obtained from this study indicate that BRCAl and B RC A l 
genes are involved in the development of some but not all hereditary 
breast cancers in the Turkish population as reported for other populations 
(14,15).
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Report
The Exon 13 Duplication in the BRCA1 Gene Is a Founder Mutation 
Present in Geographically Diverse Populations
The B R C A 1  Exon 13 D up lica tion  Screening Group*
Recently, a 6-kb duplication of exon 13, which creates a frameshift in the coding sequence of the BRCAl gene, 
has been described in three unrelated U.S. families of European ancestry and in one Portuguese family. Here, our 
goal was to estimate the frequency and geographic diversity of carriers of this duplication. To do this, a collaborative 
screening study was set up that involved 39 institutions from 19 countries and included 3,580 unrelated individuals 
with a family history of the disease and 934 early-onset breast and/or ovarian cancer cases. A total of 11 additional 
families carrying this mutation were identified in Australia (1), Belgium (1), Canada (1), Great Britain (6), and the 
United States (2). Haplotyping showed that they are likely to derive from a common ancestor, possibly of northern 
British origin. Our results demonstrate that it is strongly advisable, for laboratories carrying out screening either 
in English-speaking countries or in countries with historical links with Britain, to include within their BRCAl 
screening protocols the polymerase chain reaction-based assay described in this report.
Methods used to screen for mutations in the BRCAl 
gene (MIM 1Î3705) focus mainly on genomic DNA, 
and, being PCR based, they do nor enable the detection 
of large DNA rearrangements. This may explain why 
only 12 large germline insertions or deletions have been 
described (Petrij-Bosch et al. 1997; Puget et al. 1997, 
1999a, 1999b; Swensen et al. 1997; Montagna et al. 
1999; Rohlfs et al. 2000), compared with MOO point 
mutations, small insertions, and deletions scattered 
across the whole coding sequence and over the splice 
junctions (Breast Cancer Information Core). However, 
in two independent studies performed on Dutch (Petrij- 
Bosch et al. 1997) and U.S. (Puget et al. 1999a) families 
with breast and/or ovarian cancer, rearrangements have 
been found to represent 36% and 15% of all mutations, 
respectively.
Recently, a 6-kb duplication of exon 13, ins6kbExl3, 
which creates a frameshift in the coding sequence, has 
been identified in the BRCAl gene (Puget et al. 1999b). 
It was initially found in three, apparently unrelated, U.S. 
families of European ancestry and in one Portuguese
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family. Haplotype data suggested a common founder for 
all these families.
To estimate the frequency and geographic diversity of 
carriers of this duplication, which will not be identified 
if not specifically sought, a collaborative study was set 
up. This involved 39 institutions in which the screening 
for ins6kbExl3 was done by PCR (fig. 1) using specific 
primers and a positive control. A total of 3,580 unrelated 
individuals with a family history of breast and/or ovar­
ian cancer who were from 19 different countries (Aus­
tralia, Austria, Belgium, Canada, Finland, France, Ger­
many, Great Britain, Hungary, Ireland, Israel, Italy, the 
Netherlands, Norway, Spain, Sweden, Switzerland, Tur­
key, and the United States) were screened. To be enrolled, 
the family histories had to fulfill at least one of the fol­
lowing criteria: (1) at least three cases of female breast 
and/or ovarian cancer; (2) at least one case of female 
breast cancer and one case of male breast cancer; (3) 
one case of female breast cancer diagnosed at age <50 
years and one case of ovarian or female breast cancer; 
(4) one case of female breast cancer and one case of 
ovarian cancer in first-degree relatives; (5) one case of 
female breast cancer and one case of female bilateral 
breast cancer; or (6) two cases of ovarian cancer. This 
heterogeneous sample is representative of the diversity 
of patients who attend clinics for individuals at high risk 
for cancer. At the time of the analysis, the whole coding 
sequence and the splice sites of the B R C A l  and B RC A 2  
genes had been screened for the presence oi mutations
20/
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Figure 1 Schematic representation of BRCAl exon 13 duplication. The location and orientation of the dupl3F (GAT TAT TTC CCC 
CCA GGC TA) and dupl3R (AGA TCA TTA GCA AGG ACC TGT G) primers are represented, along with the position of the 6-kb duplicated 
region and of the 1.1-kb PCR fragment generated with dupl3F/R. Blackened boxes denote exons; dotted lines denote intron 12; and broken 
lines denote intron 13.
in 61 % and 37%, respectively, of the families; the screen­
ing had not been completed in 31% (BRCAl) and 43% 
of them (BRCAl); it had not been attempted in 8% 
(BRCAl) and 20% (BRCAl).
From this series of families, 1,831 \vere recruited and 
screened in English-speaking countries, and 10 appar­
ently independent families were found to carry the du ­
plication in Australia (1), Canada (1), Great Britain (6), 
and the United States (2) (table 1). No duplications were 
found in the 1,749 families who were recruited and 
screened in non-English-speaking countries (table 2). 
Ten of the institutions involved in this project also sought 
the presence of the duplication in 934 additional sam­
ples, mainly breast cancer cases selected for an early age 
at onset (table 3). One non-English-speaking duplica­
tion carrier was found in this second series: a Belgian 
woman with breast cancer diagnosed at age 34 years 
whose mother also developed breast cancer. If we also 
include the 4 families previously identified (Puget et al. 
1999(3), a total of 15 apparently unrelated families have 
been found to carry ins6kbExl3 (table 4). As seen with 
the other recurrent mutations (Tonin et al. 1996), these 
15 families display a spectrum of different breast and 
ovarian cancer phenotypes.
Haplotype analysis was conducted with seven poly­
morphic short-tandem-repeat markers within or flank-
Table 1
BRCAl  E x o n  1 3 - D u p l i c a t i o n  S c r e e n i n g  in  E n g l i s h - S p e a k i n g  C o u n t r i e s
N o .  OF
N o .  OF Sc r e e n e d  Families"
C o u n t r y  
AND T o w n
Posit ive
Famliies Total
Breast Cancer 
Only
Breast and 
Ovarian Cancer
Ovarian Cancer 
Only
Australia:
Westmead 1 40 33 7 0
Canada:
Montreal 0 5*' 1 4 0
Toronto 1 5 0 4 31 9 174 11
Ireland:
Dublin 0 73 15 50 8
United Kingdom:
Cambridge 0 56 0 15 41
St Andrews 1 150 112 38 0
Leeds 4 44 0 44 0
London r..; 278 21 0 68 0Sutton 94 NC NC NC
United States:
Chapel Hill 0 61 39 21 1
New Y(jrk 0 92 64 27 1
Philadelphia 1 110 65 45 0
Rochester 1 2 5 7 206 51 0
Salt Lake City 0 6 7 43 24 0
Total 10 1,831 > 1 ,1 0 7 >568 > 62
■* NC] = nor communicared.
'* No French Canadian or Jewish Ashkenazi families were included.
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Table 2
BRCA7 E x o n  1 3 - D u p l i c a ( i o n  S c r e e n i n g  in  N o n - E n g l i s h - S p e a k i n g  C o u n t r i e s
N o .  o r
N o .  O F  S c r e e n e d  F a m i l i e s
C o u n t r y  
A N D  T o w n
P o s i t i v e
F a m i l i e s Total
Breast Cancer 
Only
Breast and 
Ovarian Cancer
Ovarian Cancer 
Only
Austria:
Vienna 0 2 3 8 177 52 9
Belgium:
Gent 0 30 26 3 1
Canada:
Quebec 0 45 40 5 0
Finland:
Helsinki 0 161 126 35 0
France:
Clermont-Ferrand 0 36 24 9 3
Lille 0 115 103 5 7
Nantes 0 48 39 8 1
Villejuif 0 70 46 24 0
Paris 0 51 44 7 0
St. Cloud 0 1 17 96 20 1
Germany:
Dusseldorf 0 45 36 8 1
Heidelberg 0 75 52 22 1
Hungary:
Budapest 0 25 24 1 0
Israel:
Tel Hashomer 0 76 62 14 0
Italy:
Milan 0 48 35 13 0
Padua 0 96 54 33 9
Pisa 0 17 3 14 0
Netherlands:
Leiden 0 30 26 4 Ô
Utrecht 0 2 0 0 168 27 5
Norway:
O s l o 0 19 1 13 5
Spain:
Barcelona 0 85 58 27 0
Madrid 0 76 60 16 0
Sweden:
Lund 0 2 9 0 20 9
Switzerland:
Geneva 0 8 6 2 0
Turkey:
Ankara 0 9 8 0 1
Total 0 1 ,749 1 ,314 382 53
ing the BRCAl locus and spanning '-'1.9 Mb (from 
centromere to telomere, these markers are D17S1185, 
D17S1321, D17S1323, D17S1322, D17S855, D17S1326, 
and D17S1325; data not shown). In 8 of the 15 families, 
a single sample was available; thus, it w^s not possible 
to determine phase. Nevertheless, all exon 13-duplica- 
tion carriers had genotypes compatible with their shar­
ing the same haplotype. Because the particular alleles 
shared by duplication carriers at D17S1185 and 
D17S855 have population frequencies <15%, we can 
conclude that this duplication has most likely spread 
From a common ancestor. Unfortunately, because of an 
insufficient number of families in which haplotypes
could be determined, it was not possible to accurately 
date this mutation.
We then tried to determine where the duplication orig­
inated. The origins of three of the families positive for 
the duplication could not be traced (table 4). However, 
the remaining ones are, in all but one case, compatible 
with the assumption that the ancestor for this mutation 
was British, because they are either of British descent or 
from countries—Ireland, Portugal, and Belgium—that 
have trading or other historical links with Britain. Five 
of the British families are from northern England, mainly 
Yorkshire, suggesting a northern British origin for the 
ancestor of this mutation. The exception is a U.S. family
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Table 3
BRCA1 E x o n  1 3 - D u p l i c a t i o n  S c r e e n i n g  in  B r e a s t  a n d / o r  O v a r i a n  C a n c e r  C a s e s
A m . J. H u m . G en e t. 6 7 :Z 0 7 -Z 1 2 , ZOOO
N o .  o r
N o .  { A g e  [ Y e a r s ])  o f  S c r e e n e d  C a s e s
C o u n t r y  
A N D  T o w n
P o s i t i v e
C a s e s Breast Cancer
Breast and
Ovarian Cancer Ovarian Cancer
Canada:
Toronto 0 2 4  (<45) 5
Ireland:
Dublin 0 14 (<50)
United Kingdom: 
London 0 5 9  {<35) 2
Sutton 0 6 1 7  (<45)
Austria:
Vienna 0 14 (<35) 4 (<40)
Belgium:
Gent 1 16 (<35) 1 (<35)
Germany:
Dusseldorf 0 2 « 4 0 )
Heidelberg 0 7 0  (<40)
Spain:
Barcelona 0 90  (<35)
Turkey:
Ankara 0 16 (<32)
Total 1 9 2 2 5 y
of Norwegian and Swedish ancestries. Another possi­
bility is that the duplication could be of Viking origin, 
since all the countries mentioned above also had contact 
with Vikings. However, against this possibility, no du­
plication carrier has been identified in Sweden or in Nor­
way; but the number of families screened was low in 
both countries (19 and 19, respectively; table 2). Alter­
natively, this U.S. carrier may not be fully aware of all 
her ancestors.
Eleven more families have been identified as carrying
the exon 13 duplication, either in different series or after 
this study: two from Australia, one from New Zealand 
(E. Edkins, personal communication), five from Canada 
(S. Narod and C. Phelan, personal communication; N. 
Carson, personal communication), and three from Great 
Britain (A. Haworth, personal communication). In con­
clusion, the BRCAl exon 13 duplication is most likely 
a founder mutation distributed mainly in English-speak­
ing countries or in countries with historical links with 
Britain. It would be strongly advisable, for laboratories
Table 4
O r i g i n  a n d  P h e n o t y p e  o f  t h e  F a m i li e s  C a r r y i n g  t h e  BRCAl E x o n  1 3  D u p l i c a t i o n
T o w n  W h e r e  S c r e e n i n g  W a s  D o n e N a t i o n a l i t y O r i g i n
N o .  O F C a s e s
Breast Cancer Ovarian Cancer
Lyon"· (France) American Irish/Dutch 1 4
Lyon“(France) American English 7 3
Lyon''(France) American Unknown 7 0
Lyon“(France) Portuguese Portuguese 3 0
Gent (Belgium) Belgian Unknown 2 0
Perth (Australia) Australian Unknown 4 1
Toronto (Canada) American Irish/Scottish/English/German 4 0
St. Andrews (Great Britain) British English/Polish 3 0
Leeds (Great Britain) British English 3 3
Leeds (Great Britain) British English 2 3
Leeds (Great Britain) British French/English 4 1
Leeds (Great Britain) British English 5 1
l.ondon (Great Britain) British English 1 2
Philadelphia (United States) American Du tch/German/French/English 8 3
Rochester (United States) American Norwegian/Swedish 4 0
Total 58 21
Families reported by Puget er al. (1999^ /).
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carrying out screening for BRCAl mutations in these 
countries, to include within their protocols the PCR- 
based assay described here. This study emphasizes once 
more the necessity of screening not only for mutations 
in the coding sequence and splice sites but also for gene 
rearrangements, when one is analyzing for the presence 
of disease-causing mutations in the BRCAl gene.
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